<SEC-DOCUMENT>0001213900-20-009853.txt : 20200422
<SEC-HEADER>0001213900-20-009853.hdr.sgml : 20200422
<ACCEPTANCE-DATETIME>20200422172719
ACCESSION NUMBER:		0001213900-20-009853
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200422
DATE AS OF CHANGE:		20200422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-216748
		FILM NUMBER:		20808635

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea120950-424b5_actinium.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Registration No. 333-216748</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Prospectus
Supplement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(To Prospectus Dated October 12, 2017)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>100,833,333
Shares Common Stock</B></FONT></P>

<P STYLE="font: 10pt/14.4pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Pre-Funded
Warrants to Purchase up to 82,500,001 Shares of Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are offering
100,833,333 shares of our common stock, par value $0.001 per share. Each share of common stock is being sold at a
public offering price of $0.15 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are also offering pre-funded warrants
to purchase up to an aggregate of 82,500,001 shares of common stock, which we refer to herein as the pre-funded warrants, to
institutional investors whose purchase of shares of common stock in this offering would otherwise result in such purchasers,
together with their affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the
purchasers, 9.99%) of our outstanding shares of common stock immediately following the closing of this offering. Subject to
limited exceptions, a holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded
warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the
holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. This
offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering.
Each pre-funded warrant is being sold at a public offering price of $0.1499 per pre-funded warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each pre-funded warrant will have an exercise
price per share of common stock equal to $0.0001 and is exercisable at any time after its original issuance until exercised in
full.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is presently traded on the NYSE American under
the symbol &ldquo;ATNM.&rdquo; There is no established trading market for the pre-funded warrants, and we do not expect a market
to develop. We do not intend to apply for a listing for the pre-funded warrants on any securities exchange or other nationally
recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited. On April
20, 2020, the last reported sale price of our common stock was $0.2419 per share.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in the common stock and our
pre-funded warrants involves risks. See &ldquo;Risk Factors&rdquo; beginning on page S-8 of this prospectus supplement.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Pre-Funded Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.1499</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">27,491,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting discounts and commissions</B><SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.0105</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.0105</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,925,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Proceeds, before expenses, to Actinium Pharmaceuticals, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.1394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,566,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 7pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to reimburse the underwriters for certain expenses. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The underwriters may also purchase up to
an aggregate of &nbsp;27,500,000 additional shares of our common stock at the public offering price, less the underwriting
discounts and commissions, within 30 days from the date of this prospectus supplement to cover the underwriters&rsquo; option
to purchase additional shares. If the underwriters exercise the option in full, the total underwriting discounts and
commissions will be $2,213,750 and the total net proceeds, before expenses, to us will be $29,403,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Delivery of the shares of common stock will
be made through the book-entry facilities of The Depository Trust Company. Delivery of the pre-funded warrants will be made by
physical delivery. We anticipate that delivery of the shares of common stock and pre-funded warrants will be made on or about
&nbsp;April 24, 2020, subject to customary closing conditions.</P>



<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>H.C.
Wainwright &amp; Co.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Co-Managers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; width: 33%; vertical-align: bottom"><FONT STYLE="font-size: 12pt"><B>Maxim Group LLC</B></FONT></TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 33%; vertical-align: bottom"><FONT STYLE="font-size: 12pt"><B>JonesTrading</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B></B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
April 21, 2020</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pages</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Prospectus Supplement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_001">About this Prospectus Supplement</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-ii</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_002">Prospectus Supplement Summary</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_003">The Offering</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_004">Risk Factors</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_005">Special Note Regarding Forward-Looking Statements</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-29</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#a_006">Use of Proceeds</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#a_007">Dilution</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-31</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_008">Description of Securities we are Offering</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#a_009">Underwriting</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-34</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Notice to Investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_010">Legal Matters</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#a_011">Experts</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_012">Where You Can Find More Information</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#a_013">Incorporation of Certain Information by Reference</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-43</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; text-indent: -10pt; padding-left: 10pt">Prospectus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_001">About this Prospectus</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_002">Prospectus Summary</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_003">Risk Factors</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_004">Special Note Regarding Forward-Looking Statements</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_005">Use of Proceeds</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_006">Description of Capital Stock</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_007">Description of Debt Securities</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#pa_008">Description Of Warrants</A></P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_009">Description of Rights</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_010">Description of Purchase Contracts</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_011">Description of Units</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_012">Plan of Distribution</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_013">Legal Matters</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_014">Experts</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_015">Where You Can Find More Information</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_016">Incorporation of Certain Information by Reference</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">33</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><FONT STYLE="text-transform: uppercase"><B>About
this Prospectus Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus form a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission utilizing
a &ldquo;shelf&rdquo; registration process. This document is in two parts. The first part is the prospectus supplement, which describes
the specific terms of this offering. The second part, the accompanying prospectus, provides more general information about the
securities we may offer from time to time, some of which may not apply to the securities offered by this prospectus supplement.
Generally, when we refer to this prospectus, we are referring to both parts of this document combined. Before you invest, you should
carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein,
and the additional information described under &ldquo;Where You Can Find More Information&rdquo; in this prospectus
supplement. These documents contain information you should consider when making your investment decision. This prospectus supplement
may add, update or change information contained in the accompanying prospectus. To the extent that any statement that we make in
this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by
reference therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying
prospectus and such documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither we nor the underwriters have authorized
any other person to provide you with any information that is different. We are offering to sell, and seeking offers to buy, our
securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying
prospectus and the offering of the securities in certain jurisdictions may be restricted by law. Persons outside the United States
who come into possession of this prospectus supplement and/or the accompanying prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement and/or the accompanying
prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not
be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement
and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer
or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for
the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty
or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the context otherwise requires, references
in this prospectus supplement to &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Actinium Pharmaceuticals, Inc.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><FONT STYLE="text-transform: uppercase"><B>Prospectus
Supplement Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This summary highlights selected information
about our company, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying prospectus,
in the documents we incorporate by reference and in any free writing prospectus that we have authorized for use in connection with
this offering. This summary is not complete and does not contain all the information that you should consider before investing
in our securities. You should read this entire prospectus supplement and the accompanying prospectus carefully, including the &ldquo;Risk
Factors&rdquo; contained in this prospectus supplement, the accompanying prospectus and the financial statements and the notes
thereto incorporated by reference in this prospectus supplement and the accompanying prospectus and any free writing prospectus
that we have authorized for use in connection with this offering, before making an investment decision. This prospectus supplement
may add to, update or change information in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Actinium Pharmaceuticals Inc. is a clinical-stage,
biopharmaceutical company applying its proprietary platform technology and deep understanding of radiobiology to the development
and advancement of novel targeted therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic
modality that is used in the treatment of over fifty percent of all cancer patients and often combined with chemotherapy and lately
immunotherapy for greater therapeutic effect. Radiation is typically administered from outside the body which constrains the amount
that can be administered to patients due to dose limiting toxicities. In addition, due to the diffuse nature of the external radiation
beam, its usage is limited to solid tumors and cannot be used in blood cancers which are diffuse. ARCs combine the cell-killing
ability of a radioisotope payload with a targeting agent such as a monoclonal antibody, or mAb, to deliver radiation inside the
body to specific cells, to potentially generate greater efficacy and less toxicity. ARCs usage is broader than external delivered
radiation as they can be used for both solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation
and Actinium&rsquo;s clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in
multiple hematologic cancers. Our clinical programs are focused on two primary areas: targeted conditioning prior to a cell or
gene therapy procedure and therapeutics, either in combination with other agents or as a monotherapy. Actinium&rsquo;s product
development strategy is actively informed by clinical data with our ARCs in over 500 patients including the ongoing SIERRA trial. Our clinical pipeline has emanated from our AWE, or Antibody Warhead Enabling technology platform which is protected by over
110 issued and pending patents, trade secrets and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Targeted Conditioning</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Actinium is advancing the only multi-target, multi-indication
clinical-stage pipeline for targeted conditioning and the only ARC-based targeted conditioning regimens in development. Actinium&rsquo;s
ARCs for targeted conditioning are intended to potentially enable improved access to cell-based therapies with curative potential
including BMT or bone marrow transplant, ACT or adoptive cell therapy such as CAR-T and Gene Therapy, as well as improved outcomes.
Conditioning in the context of BMT, ACT or Gene Therapy is the act of depleting certain blood and immune forming cells including
bone marrow stem cells and, in some cases, diseased cells prior to transplanting new cells into a patient. Currently, conditioning
is accomplished using a combination of chemotherapeutic agents and external radiation. These non-targeted conditioning regimens
may prevent a patient from receiving a potentially curative therapy and hinder outcomes due to their toxicities. ARCs have the
potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while sparing normal
healthy cells. We use our ARCs at high isotope dose levels to achieve myeloablation, which fully depletes bone marrow stem cells
and at lower isotope dose levels to achieve lymphodepletion, which spares bone marrow stem cells from depletion. In addition, dosing
may be titrated downward from myeloablative doses to achieve partial myeloablation which may be appropriate for certain gene therapy
programs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CD45 Targeted Conditioning Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in">Our CD45 ARC is comprised of the anti-CD45
monoclonal antibody known as apamistamab (formerly BC8) and the radioisotope I-131 or Iodine-131. CD45 is an antigen expressed
on leukemia, lymphoma and myeloma cancer cells, as well as nucleated immune cells but is not expressed outside of the hematopoietic,
or blood, system. This unique expression on blood cancer and immune cells enables simultaneous depletion of both cell types making
CD45 an optimal antigen for targeted conditioning applications. CD45 is a cell surface antigen with an average expression of 200,000
copies per cell, however, it only internalizes at a rate of 10-15%. We believe our ARC approach is the most effective method to
target CD45 positive cells, as the radioisotope payload linear energy transfer can readily ablate a targeted cell without requiring
payload internalization like an antibody drug conjugate or rely on biological effector function processes like a naked antibody.
Furthermore, since CD45 expression level varies from low to high antigen density as the immune cells become more terminally differentiated,
we can selectively condition depending on the therapeutic application, from full myeloablation to transient lymphodepletion, by
adjusting the dose or intensity of the I-131 isotope payload. Full myeloablation can be achieved with high doses of I-131, as
its energy pathlength and crossfire effect can penetrate into bone marrow niches to target and deplete blood and immune system
forming bone marrow stem cells. Myeloablation is applicable to autologous or allogeneic BMT and to autologous gene edited or modified
therapies that can reconstitute a patient&rsquo;s blood and immune systems. Alternatively, low doses of I-131 can be transiently
lymphodepleting and spare a patient&rsquo;s bone marrow stem cells, which we believe is ideal for ACT applications such as CAR-T.
We intend to develop our CD45 targeted conditioning program for BMT, ACT and Gene Therapy applications for malignant and non-malignant
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<DIV STYLE="padding: 5; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our lead CD45 targeted conditioning
product candidate is Iomab-B, which uses high doses of I-131 to achieve myeloablative conditioning prior to a BMT. Iomab-B is
currently being studied in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory AML, or SIERRA, clinical
trial for targeted conditioning prior to an allogeneic BMT for patients with active, relapsed or refractory (r/r) Acute
Myeloid Leukemia, or AML, who are age 55 or older. Patients with active, r/r AML are not normally considered eligible for BMT
and the SIERRA trial is the only randomized Phase 3 trial to offer BMT as a treatment option for this patient population. The
SIERRA trial compares outcomes of patients randomized to receive Iomab-B and a BMT (the study arm) to those patients
randomized to receive physician&rsquo;s choice of salvage chemotherapy (the control arm). Salvage chemotherapy is also
defined as conventional care, as no standard of care exists for this patient population. Patients who fail to achieve a CR or
Complete Response on the control arm are ineligible to proceed to a BMT, but the trial design permits these patients to
&ldquo;cross over&rdquo; to receive the study arm treatment if they meet the eligibility criteria. The primary endpoint of
the SIERRA trial is durable Complete Remission, or dCR, of six months and the secondary endpoint is one-year Overall
Survival, or OS. When the crossover patients receive Iomab-B and BMT, they have not achieved remission with their salvage
therapy and are considered to be failures for the primary endpoint of the study. The SIERRA trial is currently active at 20
sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete
enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License
Application, or BLA, with the FDA in 2021. If approved, our initial commercial launch would target the leading 50-100 BMT and
medical centers that perform the vast majority of BMT&rsquo;s in the US today.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Safety and feasibility data from the first
75 patients enrolled on the SIERRA trial, which represents 50% of the total of 150 patients to be enrolled in the trial, was presented
in an oral presentation at the Transplantation &amp; Cellular Therapy Meetings of ASTCT and CIBMTR in February 2020. It was reported
that 100% of patients (31/31) on the study arm that received a therapeutic dose of Iomab-B received a BMT, with a median time to
BMT of 30 days, and all patients achieved neutrophil and platelet engraftment in a median time of 20 days despite a high median
blast count of 30%. On the control arm, only 18% of patients (7/38) achieved remission after salvage therapy, and then received
a BMT with a median time to BMT of 67 days and median blast count of 26%. Of the 82% of patients failing to achieve a CR with conventional
care (31/38), 20 patients were eligible to cross over to the study arm. These patients are considered as having failed the primary
endpoint of the study. All crossover patients who received the therapeutic dose of Iomab-B (20/20) received a BMT, with a median
time to BMT of 64 days and all patients achieved engraftment in a median time of 19 days despite high median blast count of 35%
at time of crossover. It was also reported that 100-day non-relapse transplant-related mortality (100-day TRM) of the study or
Iomab-B arm was 6% (2/31) of patients that received a BMT compared to 29% of patients (2/7) who received a BMT after salvage therapy
on the control arm. The universal engraftment rate and low 100-day TRM rate of the Iomab-B arm resulted in 29 patients potentially
evaluable for the primary endpoint compared to 5 patients in the control arm, a nearly six times difference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SIERRA trial is powered for up to two interim analyses of
the primary endpoint exercisable at Actinium&rsquo;s discretion and triggered by an enrollment range of 70 up to 110 patients.
The primary endpoint of SIERRA is durable Complete Remission (dCR) of 180 days. Actinium intends to exercise an ad-hoc analysis
based on the data reported from SIERRA thus far and the current status of enrollment, which could generate topline data for the
primary endpoint in late 2020 and early termination of the trial if positive. Based on the statistical plan of the study, a single
ad hoc analysis would result in a minimal alpha spend of no more than 0.00925, depending on the number of patients included in
the ad hoc analysis.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Iomab-ACT program is intended for targeted
conditioning prior to ACT or Gene Therapy and uses the same <SUP>131</SUP>I-apamistamab ARC construct as Iomab-B at varying doses.
At lower doses it is applicable for lymphodepletion prior to CAR-T or certain Gene Therapy applications where stem cell myeloablation
is not necessary. At higher doses it is applicable for Gene Therapy applications where stem cell myeloablation is necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We announced a collaboration with University
of California Davis to utilize Iomab-ACT conditioning in an ongoing Phase 1/2 trial with a novel anti-HIV autologous stem cell
gene therapy for patients with HIV-related lymphoma. This is the first Gene Therapy trial to use an ARC-based conditioning regimen.
<SUP>131</SUP>I-Apamistamab has clinical proof of concept as a targeted conditioning regimen for patients with high-risk, relapsed
or refractory lymphoma prior to an autologous stem cell transplant from a previous study, where a favorable safety profile with
no dose-limiting toxicities and minimal non-hematologic toxicities were observed and promising efficacy with median overall survival
not reached (range: 29 months to infinity) and 31% of patients in prolonged remission at a median of 36 months follow up (range:
25 &ndash; 41 months). In this study, Iomab-ACT is intended to replace the chemotherapy-based condition regimen known as BEAM
(BCNU/carmustine, etoposide, cytarabine, and melphalan) to simultaneously kill the patient&rsquo;s lymphoma cells and deplete
the patient&rsquo;s stem cells to make room for the transplant. Upon engraftment, the transplanted gene modified autologous stem
cells containing three anti-HIV genes are intended to leave the patient with a new immune system that is resistant to the HIV
virus. Iomab-ACT will be substituted for BEAM in the ongoing Phase 1/2 trial that we expect to have clinical proof of concept
data from in 2021.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe our Iomab-ACT program is highly
differentiated when compared to Fludarabine and Cyclophosphamide or Flu/Cy or other chemotherapy-based regimens that are used
as the standard of practice today for lymphodepletion prior to CAR-T. CD45 is an antigen expressed on certain immune cell types
that are relevant to the mechanism of CAR-T therapies including lymphocytes, regulatory T cells and macrophages that have been
associated with clinical responses that may limit the safety and efficacy of these CAR-T therapies including Cytokine Release
Syndrome, or CRS, and neurotoxicity, as well as durability of response. Some of these limitations may be attributable to the chemotherapy-based
conditioning agents that are being used currently prior to CAR-T therapies. Preclinical data supporting the rational for our Iomab-ACT
program was presented at multiple medical conferences in 2019. Unlike chemotherapy, preclinical data suggests Iomab-ACT is targeted
in nature and, due to this targeted effect, we expect we can improve CAR-T cell expansion more efficiently, potentially resulting
in responses that are more durable but also result in reduced CAR-T related toxicities. Importantly, we expect the Iomab-ACT program
construct to enable lymphodepletion through a single-dose, outpatient administration versus Flu/Cy or other chemotherapy-based
lymphodepletion regimens that can require multiple infusion cycles over several days. Because of this potentially superior profile,
the Iomab-ACT construct could result in improved access to CAR-T therapy and better outcomes. We intend to begin a clinical trial
with <SUP>131</SUP>I-apamistamab as a targeted conditioning agent prior to CAR-T subject to identifying a suitable partner and
we expect to have Phase 1 clinical proof of concept data in 2021.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CD33 Program: Targeted Conditioning, Combinations and Therapeutics
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our CD33 program is evaluating the clinical
utility of an ARC comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 or Ac-225.
CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome, or MDS, as well as approximately one third
of patients with multiple myeloma. Our CD33 development program is driven by data obtained from over one hundred treated patients,
including results from a Phase 1/2 trial that was conducted in 58 patients with newly diagnosed AML, which was completed in 2018.
This clinical data, as well as our current and prior experience with Iomab-B, is shaping a two-pronged approach with our CD33 program,
where at high doses we are using it for targeted conditioning and at low doses we are using it for therapeutic purposes in combination
with other modalities, or as a single agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Actimab-MDS is our second clinical trial
focused on targeted conditioning, in this case for patients with high-risk MDS and is our second pivotal program. Actimab-MDS is
informed by prior experience with our CD33 ARC in multiple trials for patients with AML, MDS and for patients that have progressed
from MDS to AML, which is also known as secondary AML. Data from these trials showed that our CD33 ARC had single-agent activity
capable of producing complete remissions (CRs) in certain patients at varying dose levels with minimal non-hematologic extramedullary
toxicities. However, dose-dependent myelosuppression, a class effect of CD33 directed therapies, was seen in many of these patients.
Given that myelosuppression is necessary prior to a BMT and, that a BMT can rescue patients with myelosuppression, we decided to
pursue a trial in targeted conditioning in high-risk MDS patients with this ARC in combination with Reduced Intensity Conditioning,
or RIC, regimens. RIC regimens are comprised of low doses of chemotherapies such as fludarabine, cytarabine, busulfan or melphalan.
A BMT is the only curative treatment option for these patients with high-risk MDS who have poor, or very poor cytogenetics. However,
these patients have poor outcomes due to high relapse rates following a BMT. Based on our interactions with FDA to date, we will
conduct a Phase 1 dose-finding clinical trial that will be followed by a randomized trial that, depending on the results observed,
may potentially serve as a pivotal trial to support the submission of a BLA. We are currently finalizing the protocol for the Phase
1 trial with the FDA, as well as the pathway to a pivotal trial. Subject to feedback from the FDA, we expect to initiate the Phase
1 portion (expected enrollment 7-18 patients) of this pivotal program in the second half of 2020 and advance to the randomized
registration trial in 2021</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our CD33 development program is also studying
the construct at various dose levels and dosing regimens either in combination or alone in multiple hematologic disease indications.
We currently have multiple clinical trials ongoing, in startup phase and in planning, to study our CD33 ARC in combination with
other therapeutic modalities such as chemotherapy, targeted agents or immunotherapy. We believe that radiation can be synergistic
when used in combination with these modalities based on mechanistic rationale supported by our own clinical data, preclinical research
and scientific evidence in the literature. We are also studying our CD33 ARC as a monotherapy in the case of MM. Our CD33 ARC development
program encompasses the following ongoing and planned trials:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Combination Trials</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase&nbsp;1 investigator
initiated Actimab-A + CLAG-M combination trial with the salvage chemotherapy regimen CLAG-M (cladribine, cytarabine, filgrastim
and mitoxantrone) for patients with relapsed or refractory AML at the Medical College of Wisconsin. At the 2019 American Society
of Hematology Annual Meeting, it was reported that 86% of patients (6/7) receiving 0.50 &micro;Ci/kg of Actimab-A, and CLAG-M
achieved a complete remission after receiving Actimab-A + CLAG-M, which is nearly 60% greater than the 55% remission rate observed
in a study of CLAG-M alone conducted at MCW in the same r/r AML patient population. In addition, 71% of these patients (5/7) achieved
negative minimal residual disease status, indicating that these are deep remissions. The 0.50 &micro;Ci/kg dose of Actimab-A was
shown to be subtherapeutic as a single agent., Since the combination to date has been well tolerated, the study progressed to
the third and final cohort that will study Actimab-A at a dose of 0.75 &micro;Ci/kg in March 2020 and we expect to complete this
trial by the end of 2020. Upon completion, we intend to explore a regulatory pathway for a pivotal trial that could potentially
support a registration. The combination of Actimab-A + CLAG-M is supported by mechanistic rationale for combining inhibitors of
DNA replication and/or repair processes such as mitoxantrone, a topoisomerase-II inhibitor, and radiation, as imparted by tumor
targeting of Ac-225 with Actimab-A. The Actimab-A + CLAG-M combination study has provided proof of principle that the addition
of subtherapeutic doses of Actimab-A to other AML therapies can lead to well tolerated regimens with improved responses.&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 24px">&nbsp;</TD>
    <TD>Phase 1 Actimab-A + Ven combination trial with the BCL-2 inhibitor
Venetoclax (Ven) for patients with relapsed or refractory AML. This trial will be led by UCLA Medical Center and will be conducted
at three additional trial sites. This combination is supported by mechanistic evidence in preclinical studies using Ven-resistant
AML tumor cell lines. In these models, we have demonstrated that Actimab-A can deplete Mcl-1 and Bcl-XL, two proteins implicated
in mediating resistance to venetoclax, in addition to causing potentially lethal double-stranded DNA breaks in these CD33 targeted
cells. Furthermore, in vivo studies in animal models of Ven-resistant AML demonstrated robust tumor regression and improved survival
in cohorts receiving the Actimab-A Ven combination compared to Ven alone. The rationale for this clinical study is that the addition
of Actimab-A will; 1) have a direct anti-tumor effect via double-stranded DNA breaks and 2) deplete Mcl-1 and BCL-XL making the
AML cells more susceptible to Ven. We expect to initiate the trial and have preliminary proof of concept clinical data from this combination
study by the end of 2020.</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 Actimab-A +
7+3 combination trial in patients with newly diagnosed AML with intermediate or high-risk cytogenetics or molecular markers. In
February 2020, we announced plans to initiate this combination trial to add Actimab-A to 7+3, which is the standard of care chemotherapy
regimen comprised of cytarabine and daunorubicin for patients with newly diagnosed AML who are fit for intensive therapy. As we
have seen with the combination of Actimab-A + CLAG-M chemotherapy, we believe that Actimab-A will have synergistic and potentiating
properties when added to 7+3, which causes DNA damage and has radiation sensitizing properties since daunorubicin is an anthracycline
antibiotic that cytotoxically inhibits DNA replication and repair and RNA synthesis through inhibition of topoisomerase II. The
rationale for studying Actimab-A in combination with 7+3 is the potential for both additive and synergistic effects due to the
interplay of various mechanisms including DNA damage from alpha radiation and the chemotherapy combination, radiation sensitization,
and prevention of DNA damage repair. We expect to initiate this Phase 1 trial by the end of 2020 and have proof of concept data in 2021.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Monotherapy Trial</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Multi-center Phase 1 Actimab-M trial for patients with penta
refractory MM. Approximately one third of patients with MM have CD33 expression, which is associated with poorer outcomes. MM is
exquisitely sensitive to radiation, but patients do not receive radiation currently because external delivery could result in significant
toxicities given that the disease is spread throughout the body. The rationale for this trial is to use a new therapeutic modality
of alpha radiation, which MM cells have no known resistance mechanism against, for this high-risk patient population. We have recently
initiated Memorial Sloan Kettering Cancer Center as a clinical trial site in the Actimab-M trial, which is currently active at
three other trial sites in the United States. We expect to have initial proof of concept data from this trial in 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Antibody Warhead Enabling Technology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our proprietary Antibody Warhead Enabling,
or AWE, Technology Platform is supported by intellectual property, know-how and trade secrets that cover the generation, development,
methods of use and manufacture of ARCs and certain of their components. Our AWE technology patent portfolio includes 28 patent
families comprised of over 110 issued and pending patent applications, of which 9 are issued and 23 pending in the United States,
and 81 are issued and pending internationally the useful life of which ranges from 2019 to 2039. Our proprietary technology enables
the direct labeling, or conjugation and labeling, of a biomolecular targeting agent to a radionuclide warhead and its development
and use as a therapeutic regimen for the treatment of diseases such as cancer. Our intellectual property covers ARC compositions
of matter, formulations, methods of administration, and radionuclide production. Further, our AWE intellectual property covers
various methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic
combinations. In addition, due to the renewed focus on research and technology development in 2017 and 2018, we expect the useful
life of new intellectual property filed by us, if granted, to extend well beyond the current dates in several key areas including
for next generation ARCs, combination treatments and targeted radiation approaches using the isotopes Ac-225 and I-131.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our proprietary technology includes methods
of conjugation, labeling and use of the radionuclides Ac-225 and I-131. Our technology covers the use of the &ldquo;gold standard&rdquo;
chelator, tetracarboxylic acid, an organic compound used to attach, or conjugate, the radionuclide Ac-225 to monoclonal antibodies
and any conceivable derivative thereof. Additionally, we possess intellectual property protection, know-how and trade secrets covering
efficient methods of chelation and labeling of the targeting agent with Ac-225 as well as newer next-generation methods of chelation
or labeling. We are conducting preclinical research with our AWE Technology Platform to demonstrate proof of concept in liquid
and solid tumors for various indications including targeted conditioning, lymphodepletion, combinations of ARCs with other modalities
and as monotherapies to enable research collaborations, partnerships and expand our development pipeline. In March 2018, we entered
into a collaborative research agreement with Astellas Pharma, Inc., or Astellas, that is utilizing our AWE technology platform
to create ARCs using the Ac-225 isotope and select targeting agents owned by Astellas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2020, we provided an update on the pivotal Phase 3
SIERRA trial announcing that we intend to exercise one of the two designed ad-hoc analyses, which could generate topline data for
the primary endpoint in late 2020 and early termination of the trial if positive. Our decision to exercise the ad-hoc analysis
is based on the data reported from SIERRA thus far and the fact that enrollment is approaching the upper bound of the range in
which we can exercise the analysis. At full enrollment of 150 patients, SIERRA will be deemed successful if the efficacy of Iomab-B
arm, measured by dCR rate, is at least twice that of the control arm. Based on the statistical plan of the study, a single ad hoc
analysis would result in a minimal alpha spend of no more than 0.00925, depending on the number of patients included in the ad
hoc analysis. In addition, based on feedback from investigators, we updated that a majority of the 20 SIERRA trial sites, including
top enrolling sites, are continuing to recruit and enroll patients with March having higher than average enrollment despite COVID-19.
Actinium anticipates that sites currently not actively enrolling due to COVID-19 will likely resume recruitment and enrollment
in the summer timeframe</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2020, we announced the expansion
of our CD33 program with a combination trial of Actimab-A with the standard of care 7+3 chemotherapy regimen in patients with newly
diagnosed AML who have intermediate or high-risk cytogenetics of molecular markers. This Phase 1 trial will be led by Columbia
University Herbert Irving Comprehensive Cancer Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2020, we announced a clinical
collaboration with UC Davis to use our Iomab-ACT program (apamistamab-I-131) as a targeted conditioning agent with an autologous
anti-HIV stem gene therapy that is being studied in an ongoing Phase 1/2 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2019, interim results were presented in a poster
presentation at the American Society of Hematology Annual Meeting from our ongoing Phase 1 trial of Actimab-A in combination with
the chemotherapy regimen CLAG-M in patients with relapsed or refractory AML. It was reported that 86% of patients (6/7) receiving
0.50 &micro;Ci/kg of Actimab-A, a dose that was shown to be subtherapeutic as a single agent, and CLAG-M achieved a complete remission
after receiving Actimab-A + CLAG-M, which is nearly 60% greater than the 54% remission rate observed in a study of CLAG-M alone.
In addition, 71% of patients (5/7) achieved negative minimal residual disease status, indicating that deep remissions were attained.
Actinium intends to conduct larger and more complex randomized trials to confirm the significance of these preliminary results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Since January 2020, we sold 9.5 million shares
of common stock through our At-the-Market facility for gross proceeds of $2.6 million and sold 0.8 million shares of common stock
under a purchase agreement with Lincoln Park Capital Fund, LLC for gross proceeds of $0.2 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2019, the balance of
our cash and cash equivalents was $9.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate and Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were organized in the State of Nevada
in October 1997 and reorganized in the State of Delaware in March 2013. Our principal executive offices are located at 275 Madison
Avenue, 7th Floor, New York, New York 10016. Our telephone number is (646) 677-3870. Our website address is <I>www.actiniumpharma.com</I>.
Information accessed through our website is not incorporated into this prospectus supplement and is not a part of this prospectus
supplement or the accompanying prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium Pharmaceuticals, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Offered by Us</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,833,333&nbsp;shares of common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded warrants offered by us</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded&nbsp;warrants to purchase up to an aggregate of&nbsp;&nbsp;82,500,001&nbsp;shares of common stock. We are offering the pre-funded warrants to institutional investors whose purchase of shares of common stock in this offering would otherwise result in such purchasers, together with their affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchasers, 9.99%) of our outstanding shares of common stock immediately following the closing of this offering. Each pre-funded warrant is exercisable for one share of common stock. Each pre-funded warrant is being sold at a public offering price of $0.1499. Each pre-funded warrant will have an exercise price per share of common stock of $0.0001, and will be immediately exercisable and may be exercised at any time until exercised in full. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of the pre-funded warrants. The exercise price and number of shares of common stock issuable upon exercise will be subject to certain further adjustments as described herein.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock to be Outstanding Immediately After this Offering</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
358,343,700&nbsp;shares (or 385,843,700 shares if the underwriters exercise their option to purchase additional shares in full), in each case assuming all of the pre-funded warrants issued in this offering are exercised.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option to purchase additional shares</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We have granted the underwriters an option to purchase up to </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;27,500,000&nbsp;<FONT STYLE="background-color: white">additional shares of common stock from us at the public offering price per share, less underwriting discounts and commissions. This option is exercisable, in whole or in part, for a period of 30 days from the date of this prospectus supplement.</FONT></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"></P></DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 60%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We estimate that our net proceeds from our issuance and sale
of shares of our common stock and pre-funded warrants to purchase shares of common stock in this offering will be
approximately $25.3 million, after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If the underwriters exercise their option to purchase additional
shares of common stock in full, we estimate the net proceeds from this offering will be approximately $29.1 million
from the sale of our securities, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds from the sale of
        securities offered by this prospectus supplement to complete our ongoing pivotal, Phase 3 SIERRA trial for our lead product candidate
        Iomab-B and progress Phase 1 trials from our refocused CD33 program to the proof of concept stage. We will also use the net proceeds
        to support our AWE Technology Platform including our Iomab-ACT program, research and development and general working capital needs.
        See the section entitled &ldquo;Use of Proceeds&rdquo; below.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common shares involves a high degree of risk. For a discussion of factors that you should consider before buying our securities, see the information under &ldquo;Risk Factors&rdquo; in this prospectus supplement and under similar headings in the documents incorporated by reference into this prospectus supplement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American symbol</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ATNM.&rdquo;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The number of shares of our common stock that
will be outstanding immediately after the offering is based on 175,010,366 shares outstanding as of April 20, 2020. Unless we specifically
state otherwise, the share information in this prospectus supplement excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,037,571 shares of common stock issuable upon the exercise of stock options outstanding as of April 20, 2020 under our equity incentive plans, with a weighted average exercise price of $1.19 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,149,819 shares of common stock available for future grants under our equity incentive plans as of April 20, 2020; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -6pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,140,575 shares of common stock issuable upon the exercise of warrants outstanding as of April 20, 2020, with a weighted average exercise price of $0.69 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, this prospectus
supplement reflects and assumes no exercise by the underwriters of their option to purchase additional shares.</P>

</DiV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>An investment in our securities involves
a high degree of risk. Prior to making a decision about investing in our securities, you should carefully consider the specific
factors discussed below, together with all of the other information contained or incorporated by reference in this prospectus supplement
and the accompanying prospectus, including in our Annual Report on Form 10-K and any updates described in our Quarterly Reports
on Form 10-Q or other documents filed by us with the SEC. It is not possible to predict or identify all such risks. Consequently,
we could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial
to our operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Recurring losses and negative cash
flows from operations raise substantial doubt about our ability to continue as a going concern and we may not be able to continue
as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our recurring losses
from operations and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern.
Substantial doubt about our ability to continue as a going concern may create negative reactions to the price of the common shares
of our stock and we may have a more difficult time obtaining financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have prepared our
financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue
in existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are a clinical-stage company and have generated no
revenue from commercial sales to date. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We are a clinical-stage
biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and have not generated
any revenue from product sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies
in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have incurred net losses in every year since our inception
and anticipate that we will continue to incur net losses in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We are not profitable
and have incurred losses in each period since our inception. As of September 30, 2019, and December 31, 2018, we had an accumulated
deficit of $204.2 million and $186.9 million, respectively. We reported a net loss of $17.3 million for the nine months ended September
30, 2019 and 2018. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance
that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be
no assurance that if such products are approved, they will be successfully commercialized, which would have an adverse effect on
our business prospects, financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We do not currently
have sufficient funding for the completion of development nor commercialization of our product candidates and we will need to continue
to seek capital from time to time to continue development of our product candidates and to acquire and develop other product candidates.
Our first product candidate is not expected to be commercialized, if approved, until at least 2021 and any partnering revenues
that it may generate may not be sufficient to fund our ongoing operations. Any partnering revenues generated by licensing activities
may not be sufficient to fund ongoing operations. Further, our other product candidates are not expected to be approved for several
years and may not generate sufficient revenues from our licensing and commercialization efforts to fund operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Presently, with no
further source of capital either via a financing or a collaboration, we project that we may run out of funds in 2020. We currently
do not have any additional source of capital secured. If we are unable to raise additional funds, we could be required to reduce
our spending plans, reduce our workforce, license one or more of our products or technologies that we would otherwise seek to commercialize
ourselves, sell all or some of our assets, cease operations or even declare bankruptcy. We will require additional cash in order
to maximize the commercial opportunity and continue clinical development of our product candidates. Alternatives available to us
to sustain our operations include collaborative agreements, equity financing, debt and other financing arrangements with potential
corporate partners and other sources. However, there can be no assurance that any such collaborative agreements or other sources
of funding will be available to us on favorable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may
be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business
or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment
or a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable
terms or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a timely enough manner
which may cause the generation of a going-concern opinion from our auditors which can and may impair our stock market valuation
and also our ability to finance on favorable terms or indeed on any terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">To raise additional
capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price
per share that is equal to or greater than the price per share paid by investors, and investors purchasing shares or other securities
in the future could have rights superior to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If we cannot raise
adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development
activities, clinical studies or future operations. We may also be required to obtain funds through arrangements with collaborators,
which arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider
relinquishing, including rights to future product candidates or certain major geographic markets. We may further have to license
our technology to others. This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these
actions may harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The amount of funding
we will need depends on many factors, including the progress, timing and scope of our product development programs; the progress,
timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the
time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter
into and maintain collaborative, licensing and other commercial relationships; and our partners&rsquo; commitment of time and resources
to the development and commercialization of our products.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We have limited access to the capital
markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have limited access
to the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and other
oncology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companies
to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends
on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at
all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If
adequate funds are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations,
financial condition and our continued viability will be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We are highly dependent on the success
of Iomab-B and the SIERRA trial and we many not able to complete the necessary clinical development or our development efforts
may not result in the data necessary to receive regulatory approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Iomab-B, which we licensed
from the Fred Hutchinson Cancer Research Center, in June 2012 is our lead program to which we allocate a significant portion of
our resources. We are currently enrolling patients in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or
Refractory AML), a 150-patient multi-center randomized trial that will compare outcomes of patients who receive Iomab-B and a BMT
to those patients receiving physician&rsquo;s choice of salvage chemotherapy, defined as conventional care, as no standard of care
exists for this patient population. The SIERRA trial may be unsuccessful and fail to demonstrate a safety and efficacy profile
that is necessary to receive favorable regulatory approval. The trials DMC or Data Monitoring Committee may recommend that the
trial be stopped early for safety or efficacy concerns, which could prevent us from completing the SIERRA trial. Even if Iomab-B
receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful
commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue
operations.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may be unable to establish sales,
marketing and commercial supply capabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We do not currently
have, nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would
have to build and establish these capabilities in order to commercialize our approved product candidates. The process of establishing
commercial capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities,
we may not be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfully
commercialize any product candidate may have material adverse impacts on our business and ability to continue operations.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In December 2019, a
novel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally, to include Canada, the United States
and several European countries. The spread of COVID-19 from China to other countries has resulted in the World Health Organization
(WHO) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo; or a worldwide spread of a new disease, on March 11, 2020.
Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the
virus and have closed non-essential businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As local jurisdictions
continue to put restrictions in place, our ability to continue to operate our business may also be limited. Such events may result
in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially
affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote working and
thus far have not experienced a significant disruption or delay in our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The spread of COVID-19,
which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by,
and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption
of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity.
In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the
value of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Currently, the pivotal
Phase 3 SIERRA trial for our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with
investigators providing feedback that recruitment and enrollment will remain active because of the acute nature of the disease,
the high unmet needs of patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated
profile of Iomab-B. We currently anticipate that sites currently not actively enrolling due to COVID-19 will likely resume recruitment
and enrollment in the summer timeframe. We also believe our earlier stage clinical trials for our CD33 program will also continue
to recruit and enroll patients given the acute nature of relapsed or refractory AML. The continued spread of COVID-19 globally
could adversely affect our planned clinical trial operations, including our ability to initiate the trials on the expected timelines
and recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure
to COVID-19 if an outbreak occurs in their geography. Further, the COVID-19 outbreak could result in delays in our clinical trials
due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to
enroll in trials at this time, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictions
impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract
research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out
our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources
to our programs or to travel to sites to perform work for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Additionally, COVID-19
may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&rsquo;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The global outbreak
of COVID-19 continues to rapidly evolve. The ultimate long-term impact of COVID-19 is highly uncertain and cannot be predicted
with confidence. In addition, since COVID-19 has become a pandemic, it could materially affect our operations globally, including
at our headquarters in the New York City area and at current and future clinical trial sites, manufacturing sites and suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our business could
be adversely affected by health epidemics in regions where our supply and manufacturing, clinical trial sites, other vendors or
other business operations are located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The ultimate impact
of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent
of potential delays or impacts on our business, our supply chain, clinical trials, healthcare systems or the global economy as
a whole. However, these effects could have a material impact on our operations, and, therefore, we will continue to monitor the
COVID-19 situation closely and implement risk mitigation as needed.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B>Risks Related to Regulation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our products are subject
to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking
regulatory approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the
effort and expense incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products
from the FDA, we may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA
permits commercial distribution of a new antibody radiation-conjugate product only after a Biologics License Application (BLA)
for the product has received FDA approval. The BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will
have to be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and
labeling data, to demonstrate to the FDA&rsquo;s satisfaction the safety and efficacy of the product for its intended use. The
lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory
approval to market our product candidates, which would significantly harm our business, results of operations and prospects. In
addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more
limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent
on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include
the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing
scenarios could materially harm the commercial prospects for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The approval process
in the United States and in other countries could result in unexpected and significant costs for us and consume management&rsquo;s
time and other resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical
data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In
addition, even if we obtain approval to market our products in the United States or in other countries, the approval could be revoked,
or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty
how, or when, the FDA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals,
our financial condition and cash flow may be materially adversely affected, and our ability to grow domestically and internationally
may be limited. Additionally, even if we obtain approval, regulatory authorities may approve any of our product candidates for
fewer or more limited indications that we request. The Company&rsquo;s products may not be approved for the specific indications
that are most necessary or desirable for successful commercialization or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We have not demonstrated that any
of our products are safe and effective for any indication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We currently have two
product candidates in clinical development. In December 2015, the FDA cleared our IND filing for Iomab-B, and we are currently
enrolling patients in a randomized, controlled, pivotal, Phase 3 clinical trial. Assuming the trial meets its endpoints, it will
form the basis for a BLA. Additionally, there are physician IND trials at the FHCRC that have been conducted or are currently ongoing
at FHCRC with Iomab-B and the BC8 antibody we licensed. We have multiple clinical trials ongoing for our drug candidates under
our own sponsorship and multiple investigator-initiated trials ongoing. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may encounter substantial delays
in our clinical trials or may not be able to conduct our trials on the timelines we expect.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay,
suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could
delay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail to receive
regulatory approval:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align:left">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from institutional review boards (IRBs) or other reviewing entities at clinical sites selected for participation in our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We may suspend, or
the FDA or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time
if we or they believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs
based on similar technologies, are being exposed to unacceptable health risks or for other reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Further, individuals
involved with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation
in connection with such services. If these relationships and any related compensation to the clinical investigator carrying out
the study result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected
interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the
utility of the clinical trial itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials,
or a delay in the analysis of clinical data for our product candidates, for any of the foregoing reasons, could adversely affect
our efforts to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and
have a material adverse effect on our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Clinical trials
may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or
DSMB (Data Safety Monitoring Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory
authorities due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.55pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Modifications to our product candidates may require federal
approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The BLA application
is the vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing
in the United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our
products may require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions
and premarket approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new
approvals for a particular use or indication, we may be required to conduct additional clinical studies, which would require additional
expenditures and harm our operating results. If the products are already being used for these new indications, we may also be subject
to significant enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Conducting clinical
trials and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect
our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business
prospects, financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans, and we may fail to obtain regulatory approval of our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In June 2012, we acquired
rights to BC8 (Iomab), a clinical stage monoclonal antibody with safety and efficacy data in more than 300 patients in need of
a BMT. Iomab-B is our product candidate that links I-131 to the BC8 antibody that is being studied in an ongoing Phase 3 pivotal
trial. Product candidates utilizing this antibody would require BLA approval before they can be marketed in the United States.
We are also evaluating a lower dose of the BC8 antibody and I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy.
We are currently evaluating clinical trials that would use our construct for lymphodepletion. Our lintuzumab-Ac-225 product candidate
is also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with AML, myelodysplastic
syndrome and multiple myeloma. Product candidates utilizing the lintuzumab antibody would require BLA approval before they can
be marketed in the United States. We are in the early stages of evaluating other product candidates consisting of conjugates of
Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA may not approve
these products for the indications that are necessary or desirable for successful commercialization. The FDA may fail to approve
any BLA we submit for new product candidates or for new intended uses or indications for approved products or future product candidates.
Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Clinical trials necessary to support
approval of our product candidates are time-consuming and expensive. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, CD33 program candidates, and other product candidates,
is a time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials
are not necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable
results in later clinical trials. We have worked with the FDA to develop a clinical trial designed to test the safety and efficacy
of Iomab-B in patients with relapsed or refractory AML who are age 55 and above prior to a BMT. This trial is designed to support
a BLA filing for marketing approval by the FDA, pending results from the trial. We have also worked with the FDA to develop a regulatory
pathway for our Actimab-MDS trial that consists of a dose-confirming Phase 1 trial that can be followed by a randomized, controlled
pivotal trial that could support a BLA filing. In addition, there can be no assurance that the data generated during the trial
will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing or
approval of a BLA. Even if the data from this trial are favorable, these data may not be predictive of the results of any future
clinical trials.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Even if our clinical
trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the
FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials
does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results
of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe
and effective for the proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, lintzumab-Ac-225, or any
other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receive
FDA approval to market that product candidate in the United States for the indications sought. In addition, such an outcome could
cause us to abandon the product candidate and might delay development of others. Any delay or termination of our clinical trials
will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates
and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that
are not currently part of a product candidate&rsquo;s profile.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The intellectual property related
to antibodies we have licensed has expired or likely expired</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have dedicated research
and development activities towards improving Iomab-B&rsquo;s stability to enhance commercial usefulness of the product and now
have a proprietary formulation for which IP is pending. We have and may continue to file patents related to Iomab-B that can provide
barriers to entry but there is no certainty that these patents will be granted or such granting thereof will adequately prevent
others from seeking to replicate and use the BC8 antibody or the construct. We have pending patents related to radioimmunoconjugate
composition, formulation administration, and methods of use in solid or liquid cancers. This matter includes composition, administration,
and methods of treatment for our products Iomab-B and Actimab-A. Any competing product based on the antibody used in Iomab-B is
likely to require several years of development before achieving our product candidate&rsquo;s current status and may be subject
to significant regulatory hurdles but is nevertheless a possibility that could negatively impact our business in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">For our CD33 program,
lintuzumab-Ac225, we have pursued a broad strategy of key patent filings and anticipated regulatory protections in the US and abroad
to protect this asset and its use.&nbsp; Our final drug construct consists of the lintuzumab antibody labeled with the alpha radioisotope
Ac225. We have licensed issued patents that relate to the linker technology we use to conjugate the isotope to the antibody. We
also own issued and pending patents related to Ac225 isotope production methods and drug preparation methods. Furthermore, we have
pending patent applications covering methods of use in the treatment of disease, including therapeutic combinations, and for targeted
conditioning in preparation for cell therapy such as bone marrow transplant, which may provide protection to 2039. This approach,
we believe, provides important intellectual property protection given that key patents related to the humanized antibody, lintuzumab,
which we use in our CD33 program product candidates have expired. While it is possible that others may eventually use an antibody
with the same sequence, we believe that our pending patent portfolio will provide protection within critical areas of clinical
focus. In addition, we possess trade secrets and know-how related to the manufacturing and use of antibody radio-conjugates including
lintuzumab-Ac225. Any potentially competing product based on the lintuzumab antibody is also likely to require several years of
development before achieving our product candidate&rsquo;s current status and may be subject to significant regulatory hurdles.
Nevertheless, the development of such a molecule remains a possibility and could negatively impact our business in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The indications for
which we are developing our product candidates for are orphan drug designations, which are disease indications that affect fewer
than 200,000 patients in the United States and less than 5 in 10,000 patients in the European Union (&ldquo;EU&rdquo;). We have
received orphan drug designation for Iomab-B and our lintuzumab-CD33 ARC for patients with AML in both the United States and the
EU. As a result, if our products are to be approved, they may receive 7 years and 10 years of market exclusivity in the US and
EU, respectively. In addition, our product candidates are biologics combined with radioisotopes. The Hatch-Waxman Act requires
that a manufacturer of generic drugs, which for a biologic drug is called a biosimilar, requires that the manufacturer demonstrate
bioequivalence. We believe that due to the nature of radioisotopes having half-lives combined with the complexities of biologic
drugs it would be difficult for a manufacturer to demonstrate bioequivalence of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our CD33 program clinical trials
are testing the same drug construct </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our CD33 program is
comprised of several clinical trials including several investigator-initiated trials including AML, MDS and Multiple Myeloma that
are studying the same drug construct consisting of lintuzumab-Ac-225. Negative results from any of these trials could negatively
impact our ability to enroll or complete our other trials studying lintzumab-Ac-225. Additionally, negative outcomes including
safety concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Iodine-131 is a key
component of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global
manufacturers. Currently, there is sufficient supply of I-131 to advance our ongoing SIERRA clinical trial, support additional
trials we may undertake utilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and suppliers
and intend to have multiple qualified suppliers prior to the commercial launch of Iomab-B. While we consider I-131 to be commoditized
and obtainable through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms
that are acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Actinium-225 is a key
component of our CD33 ARC program, AWE platform and other drug candidates that we might consider for development with the Ac-225
payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department
of Energy, or DOE. The current Ac-225 currently supplied to Actinium&rsquo;s clinical trials from the DOE is derived from the natural
decay of thorium-229 from so-called &lsquo;thorium-cows&rsquo; and is able to produce sufficient quantities that are several multiples
of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase. The DOE is also producing
Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently being evaluated
by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does not impact
labelling efficiency and expected distribution. Per representations made by the Department of Energy, the capacity of Ac-225 from
this route is expected to be sufficient to supply all of Actinium&rsquo;s pipeline and commercial Ac-225 needs and support new
program expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of
Ac-225 production are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The
cyclotron production method for Ac-225 production leverages Actinium&rsquo;s proprietary technology and know-how and presents an
additional path towards production of high-quality Ac-225 that would be able to satisfy commercial needs. In addition, we are aware
of at least six other government and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan
that have, or expect to have ability to supply Ac-225 or equipment for its production within the timeframes relevant to first commercial
approval of our Ac-225 ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our contract for supply
of this isotope from the DOE must be renewed yearly, and the current contract extends through the end of 2020. While we expect
this contract will be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical
grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates
that we may develop and would materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our ability to conduct
clinical trials to advance our ARC drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other
isotopes we may choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our
isotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers
are subject to regulations and standards that are overseen by regulatory and government agencies and we have no control over our
suppliers&rsquo; compliance to these standards. Failure to comply with regulations and standards may result in their inability
to supply isotope could result in delays in our clinical trials, which could have a negative impact on our business. We have developed
intellectual property, know-how and trade secrets related to the manufacturing process of Ac-225. While we have manufactured medical
grade Ac-225 of a purity compared to the cyclotron sourced material in the past, this activity was terminated due to operating
cost reasons and we currently do not have experience in manufacturing medical grade Ac-225 and may not obtain the resources necessary
to establish our own manufacturing capabilities in future. Our inability to build out and establish our own manufacturing facilities
would require us to continue to rely on third party suppliers as we currently do. However, based on our current third-party suppliers
and potential future suppliers of Ac-225 we expect to have adequate isotope supply to support our current ongoing clinical trials,
current AWE program activities and commercialization should our drug candidates receive approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The timely completion
of clinical trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain
in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of
reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&rsquo;s primary endpoints;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&rsquo;s and patients&rsquo; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In addition, refractory
patients, which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and
therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events
related or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in
our clinical trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, which
could adversely affect our ability to advance the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our
product candidates on a timely basis.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course
of the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all
of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might
require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval
of a product candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or
halt a clinical trial while it evaluates additional information regarding the change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Any delay or termination
of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining
required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial,
and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause
an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our
product candidates or result in the failure of the clinical trial, which could adversely affect our business, operating results
and prospects. Lengthy delays in the completion of our Actimab-A clinical trials would adversely affect our business and prospects
and could cause us to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B>Risks Related to Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We rely on third parties to conduct
our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or
comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We do not have the
ability to independently conduct our pre-clinical and clinical trials for our product candidates and we must rely on third parties,
such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such
trials. Our reliance on these third parties for clinical development activities results in reduced control over these activities.
Moreover, the FDA requires us to comply with regulations and standards, commonly referred to as GCPs (good clinical practices),
for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and
accurate and that the trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities
and requirements. If we or any of our third-party contractors fail to comply with applicable GCPs, the clinical data generated
in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition,
our clinical trials must be conducted with product produced under current good manufacturing practice, or cGMP, regulations. Our
failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If our consultants,
contract research organizations and other similar entities with which we are working do not successfully carry out their contractual
duties, meet expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe
that there are a number of other third-party contractors, we could engage to continue these activities, we may not be able to enter
into arrangements with alternative third-party contractors or to do so on commercially reasonable terms, which may result in a
delay of our planned clinical trials and delayed development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors,
we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully
carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data
they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons,
our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be
able to obtain regulatory approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and
our business, operating results and prospects would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The antibodies we use in our antibody
radiation-conjugate product candidates may be subject to generic competition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We are not aware of
any existing or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our antibody radiation-conjugate
product candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these
products pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated
pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo;
based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved
by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a
biosimilar gets approved for one of the antibodies that we use, the final constructs of our drug candidates consist of an antibody,
radioisotope and in some cases a linker. Therefore, we do not believe that the final drug product of our candidates can be subject
to competition from a biosimilar as outlined in BPCIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our product candidates may never
achieve market acceptance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Iomab-B, CD33 ARC program
candidates and future product candidates that we may develop may never gain market acceptance among physicians, patients and the
medical community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual
and perceived effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of the
product; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree to
which treatments using the product are approved for reimbursement by public and private insurers; the strength of our marketing
and distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating
specific cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide
patients with sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the
use of each product candidate from influential physicians will be essential for widespread market acceptance. Our product candidates
are still in the development stage and it is premature to attempt to gain support from physicians at this time. We can provide
no assurance that such support will ever be obtained. If our product candidates do not receive such support from these physicians
and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Failure of Iomab-B,
CD33 ARC program candidates or any of our other product candidates to significantly penetrate current or new markets would negatively
impact our business financial condition and results of operations<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Even if we receive regulatory approval
of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Any regulatory approvals
that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate.
The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail
requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory
authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,
storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing
regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. In addition, the FDA
could require us to conduct another study to obtain additional safety or biomarker information. Later discovery of previously unknown
problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party
suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The FDA&rsquo;s and
other regulatory authorities&rsquo; policies may change, and additional government regulations may be enacted that could prevent,
limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow
or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain
profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Coverage and reimbursement may be
limited or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates,
if approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The commercial success
of our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage
and reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement
for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even
if our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed
all or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and
other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement
of new drugs, and, as a result, they may not cover or provide adequate payment for these products. Submission of applications for
reimbursement approval generally does not occur prior to the filing of a BLA for that product and may not be granted until many
months after BLA approval. In order to obtain coverage and reimbursement for these products, we or our commercialization partners
may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. The continuing efforts
of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence on
the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may be subject to claims that
our third-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential information
of third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have
inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&rsquo; former employers.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation
could result in substantial cost and be a distraction to our management and employees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We depend on third-party manufacturers to produce our
pre-clinical and clinical trial drug supplies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We do not currently
operate manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party
manufacturers to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates
including monoclonal antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates.
We expect to continue to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of
our existing or future manufacturers could delay clinical development, cause us to suspend or terminate development or delay or
prohibit regulatory approval of our product candidates or commercialization of any approved products. Further avenues of disruption
to our clinical or eventual commercial supply may also occur due to the sale, acquisition, business reprioritization, bankruptcy
or other unforeseen circumstances that might occur at any of our suppliers or contract manufacturing partners including an inability
to come to terms on renewal of existing contracts or new contracts. With a view to maintaining business continuity we are evaluating
alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners, however
there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity
and support our growth plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our product candidates
require precise, high-quality manufacturing. Failure by our contract manufacturer to achieve and maintain high manufacturing standards
could result in patient injury or death, product recalls or withdrawals, delays or failures in testing or delivery, cost overruns,
or other problems that could seriously hurt our business. Contract manufacturers may encounter difficulties involving production
yields, quality control, and quality assurance. These manufacturers are subject to ongoing periodic and unannounced inspections
by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and other applicable government
regulations and corresponding foreign standards; we do not have control over third-party manufacturers&rsquo; compliance with these
regulations and standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We depend on vendors
with specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered
into manufacturing and supply agreements with these third-parties and in some instances, we have agreed that they be the exclusive
manufacturer and supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply
with required regulations or breach their contractual obligations it may be difficult, or we may be unable to identify suitable
alternative third-party manufacturers. While we identify and evaluate third-party manufacturers from time to time, even if we do
identify suitable alternative third-parties, we may fail to reach agreement on contractual terms, it may be prohibitively expensive
and there can be no assurance that we can successfully complete technology transfer and development work necessary or complete
the necessary work in a timely manner. Any of which could prevent us from commencing manufacturing with third-parties. which could
cause delays or suspension of our clinical trials and pre-clinical work that may have a negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Furthermore, these
third-party contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee
strikes, or any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and
conduct (either ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability
of third-party manufacturers to consistently supply quality product when required would have a material adverse effect on our ability
to develop or commercialize our products. We have faced delays and risks associated with reliance on key third party manufacturers
in the past and may be faced with such delays and risks in the future. Any future manufacturing interruptions or related supply
issues could have an adverse effect on our company, including delays in clinical trials.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>If we are successful in obtaining
marketing approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance
on third-party manufacturers. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">To date, our product
candidates have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the
FDA or other regulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue to
rely, at least initially, on third-party specialized manufacturers to produce commercial quantities of approved products. These
manufacturers may not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic
manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and
approve. If third party manufacturers are unable to successfully increase the manufacturing capacity for a product candidate, or
we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed or
there may be a shortage in supply, which in turn could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that
will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent
on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities,
they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable
foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our
ability to develop, obtain regulatory approval for or market our product candidates, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We may have conflicts
with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones,
the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual
property developed during our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner
that is averse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay
or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness
on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty regarding
ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into
additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including
providing us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress
of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating
litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate
the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We face significant competition from
other biotechnology and pharmaceutical companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our product candidates
face, and will continue to face, intense competition from large pharmaceutical companies, as well as academic and research institutions.
We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii) emerging
competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete
with our product candidates and technologies. Because several competing companies and institutions have greater financial resources
than us, they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development,
or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we
do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory
approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition and better access to
customers than us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our product candidates may cause
undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval,
limit their commercial potential, or result in significant negative consequences </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Undesirable side effects
caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.
The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result
in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Even if any of our product candidates receives marketing approval, as greater numbers of patients use a product following its approval,
an increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or anticipated
during pre-approval clinical trials could result in a number of potentially significant negative consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Any of these events
could substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or
could harm or prevent sales of any approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We depend upon securing and protecting critical intellectual
property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We are dependent on
obtaining and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and
other jurisdictions, as well as successfully enforcing this intellectual property and defending this intellectual property against
third-party challenges. The degree of future protection of our proprietary rights is uncertain for product candidates that are
currently in the early stages of development because we cannot predict which of these product candidates will ultimately reach
the commercial market or whether the commercial versions of these product candidates will incorporate proprietary technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our patent position is highly uncertain
and involves complex legal and factual questions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Accordingly, we cannot
predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our
licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;
we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop
similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications
or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our
licensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages,
or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">As a result, our owned
and licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection
for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We or our licensors
have applied for and will continue to apply for patents for certain products. Such applications may not result in the issuance
of any patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore,
it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive
position because of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain
a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability to
protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we
license from third parties, or subsequent related filings, would adversely affect our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such
enforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further,
such litigation can go on for years and the time demands could interfere with our normal operations. There has been substantial
litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We may
become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can
because of their substantially greater financial resources. Litigation may also absorb significant management time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success.
Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws
and the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means,
these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently,
or obtain access to, the same or similar information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Certain of our patent
rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those
patents may be terminated, and we will be unable to conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>If we are found to be infringing
on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license
to continue the development or sale of our products, and/or pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities
or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued,
the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets
of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing
and marketing of the affected product or process. If any of these actions are successful, in addition to any potential liability
for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market the
affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results
of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion of
our financial resources and the efforts of our personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our ability to protect and enforce
our patents does not guarantee that we will secure the right to commercialize our patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">A patent is a limited
monopoly right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious
invention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or
using its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention
where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate
authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented
itself, cannot be commercialized if it infringes the valid patent rights of another party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We rely on confidentiality agreements
to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become
known to our competitors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We rely on trade secrets
that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached,
our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against
our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for the
damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject
us to liability for claims arising from the use or misuse of these materials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological
materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations
governing, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely
eliminate the risk of contamination or injury from these materials and we could be held liable for any damages that result, which
could exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials
we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup
and removal. Currently the costs of complying with such federal, state, local and foreign environmental regulations are not significant,
and consist primarily of waste disposal expenses. However, they could become expensive, and current or future environmental laws
or regulations may impair our research, development, production and commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Although we do not
have any international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate
significant opportunities. However, even with the cooperating of a commercialization partner, conducting drug development in foreign
countries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations;
unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting,
acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse
tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If we were to experience
any of the difficulties listed above, or any other difficulties, any international development activities and our overall financial
condition may suffer and cause us to reduce or discontinue our international development and registration efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We are highly dependent on our key
personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully
implement our business strategy. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our future operations
and successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent
upon to manage our business. If any member of our current senior management terminates his employment with us and we are unable
to find a suitable replacement quickly, the departure could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our future success
also depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical,
clinical and regulatory personnel. There can be no assurance that such professionals will be available in the market, or that we
will be able to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore, the cost
base in relation to such compensation, which may include equity compensation, may increase significantly, which could have a material
adverse effect on us. Failure to establish and maintain an effective management team and workforce could adversely affect our ability
to operate, grow and manage our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we
are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If we obtain FDA approval
for any of our product candidates and begin commercializing those products in the United States, our operations may be directly,
or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact,
among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation
by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine requirements under PPACA, which require certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Because of the breadth
of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has
strengthened these laws. For example, the PPACA, among other things, amends the intent requirement of the federal anti-kickback
and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific
intent to violate it to have committed a violation. Moreover, the PPACA provides that the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If our operations are
found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject
to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs,
such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Recent federal legislation will increase
pressure to reduce prices of pharmaceutical products paid for by Medicare, which could materially adversely affect our revenue,
if any, and our results of operations.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In the United States,
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the MMA, changed the way Medicare covers
and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced
a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the
expansion of federal coverage of drug products, we expect that there will be additional pressure to reduce costs. These cost reduction
initiatives and other provisions of this legislation could decrease the scope of coverage and the price that we receive for any
approved products and could harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction
in reimbursement that results from the MMA may cause a similar reduction in payments from private payors. This legislation may
pose an even greater risk to our drug candidates as a significant portion of the target patient population for our drug candidates
would likely be over 65 years of age and, therefore, many such patients will be covered by Medicare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In March 2010, the
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively,
the PPACA, became law in the United States. The goal of the PPACA is to reduce the cost of healthcare and substantially change
the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement
policies this legislation will have in general or on our business specifically, the PPACA may result in downward pressure on pharmaceutical
reimbursement, which could negatively affect market acceptance of our drug candidates, if approved, or any of our future products.
In 2012, members of the U.S. Congress and some state legislatures sought to overturn certain provisions of the PPACA including
those concerning the mandatory purchase of insurance. However, on June 28, 2012, the United States Supreme Court upheld the constitutionality
of these provisions. Members of the U.S. Congress have since proposed a number of legislative initiatives, including possible repeal
of the PPACA. We cannot predict the outcome or impact of current proposals or whether new proposals will be made or adopted, when
they may be adopted or what impact they may have on us if they are adopted. These challenges add to the uncertainty of the legislative
changes as part of ACA. Changes that may affect our business include those governing enrollment in federal healthcare programs,
reimbursement changes, fraud and abuse and enforcement. These changes will impact existing government healthcare programs and will
result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician
quality reporting system and feedback program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Managing our growth as we expand
operations may strain our resources.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 36.55pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We expect to need to
grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates,
which will place a significant strain on our financial, managerial and operational resources. In order to achieve and manage growth
effectively, we must continue to improve and expand our operational and financial management capabilities. Moreover, we will need
to increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses and may
require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm our business,
financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may expand our business through
the acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also
dilute current stockholders&rsquo; ownership interests in our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our business strategy
includes expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies
to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity
securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time
of acquisition; difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our management&rsquo;s
attention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and the
potential loss of our key employees or key employees of the acquired companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired
products, businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired
products, business or companies may require a substantial capital investment by us. We may not have these necessary funds, or they
might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred
or common stock, which could dilute each current stockholder&rsquo;s ownership interest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Risks Related to Ownership of Our
Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>The sale of securities by us in any
equity or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have financed our
operations primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise
additional capital through the sales of stock and warrants in order to expand our level of operations to continue our research
and development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Any sale of common
stock by us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional
shares of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing
strategic relationships with targeted customers and vendors. In order to do so, or to finance the cost of our other activities,
we may issue additional equity securities that could dilute our stockholders&rsquo; stock ownership. We may also assume additional
debt and incur impairment losses related to goodwill and other tangible assets if we acquire another company and this could negatively
impact our earnings and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our Common Stock is considered a
Penny Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">During the first nine
months of 2019, and for the years of 2018, 2017 and 2016, the price of our common stock has traded below $5.00 per share, and therefore
is treated as a penny stock. Penny stocks generally are equity securities with a price of less than $5.00. Penny stock rules require
a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure
document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide
the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson
in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account.
The broker-dealer must also make a special written determination that the penny stock is a suitable investment for the purchaser
and receive the purchaser&rsquo;s written agreement to the transaction. These requirements may have the effect of reducing the
level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities,
which could severely limit their market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers
to sell our common stock and may affect your ability to resell our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We may be required to effectuate
a reverse stock split to be able to maintain compliance with applicable listing requirements or standards of the NYSE AMERICAN
exchange or our common stock could get delisted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If our stock trades
at a depressed valuation for an extended period of time, we may be required to effectuate a reverse stock split to maintain compliance
with NYSE American listing requirements, or we could be delisted from the exchange. In addition, we may elect to seek approval
for and if authorized, effectuate a reverse stock split to increase the price of our common stock so that our stock is no longer
considered a penny stock and to make our stock more marketable to institutional investors that cannot buy stocks below certain
prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In order to effectuate
a reverse split, we would be required to obtain shareholder approval at a meeting of shareholders. We would also need the approval
of the Financial Regulatory Authority (FINRA) to effectuate a stock split. There is no guarantee that we would be successful in
obtaining the necessary approval from FINRA or the votes required to reach a quorum to hold a meeting or to authorize our Board
of Directors to approve a reverse stock split. To conduct a meeting of shareholders we would have to file and issue the required
proxy information and materials, which could take a significant amount of time. It is possible that during the proxy solicitation
process our stock would be delisted before we could obtain the necessary authorization for our Board of Directors to approve a
reverse split to regain compliance with NYSE AMERICAN listing requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">If we fail to maintain
compliance with NYSE American listing requirements and our stock is delisted, the market price and liquidity of our common stock
could be adversely impacted. This may also reduce our ability to raise additional capital. Even if we are successful in obtaining
authorization and our Board of Directors approves a reverse stock split, there can be no assurance that intuitional investors will
buy shares of our common stock. There can be no assurance that our common stock can maintain its post-reverse split price and it
may be treated as a penny stock. In the event, that our common stock is delisted from the NYSE AMERICAN or another national securities
exchange, trading of our common stock could occur in the over-the-counter market or on an electronic bulletin board established
for unlisted securities such as the OTC Bulletin Board or Pink Sheets. This could result in adverse impact on the market price
and liquidity of our common stock, a reduction in coverage by security analysts and impair our ability to raise additional capital,
all of which could cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our common stock is subject to price
volatility which could lead to losses by stockholders and potential costly security litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The trading volume
of our common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock
to fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth,
quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions
in the economy and the financial markets or other developments affecting our competitors or us. This volatility has had a significant
effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could
have the same effect on our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The trading price of
our Common Stock may be highly volatile and could fluctuate in response to factors such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Common Stock or other securities in the open market; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">The stock market is
subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&rsquo;s
securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us,
whether or not successful, could result in substantial costs and diversion of our management&rsquo;s attention and our resources,
which could harm our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>We do not intend to pay dividends
on our common stock, so any returns will be determined by the value of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We have never declared
or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from
our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our common
stock. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. There
is no guarantee that our common stock will appreciate in value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Certain provisions of our Certificate
of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult
to complete, even if such a transaction were in our stockholders&rsquo; interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change
in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the
price of our stock. Among other things, the certificate of incorporation and bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors into three classes; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align:left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&rsquo;s notice; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">In addition, we are
governed by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years
after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. A &ldquo;business combination&rdquo; includes mergers, asset sales or other transactions resulting in a
financial benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates,
owns, or within three years, did own, 15% or more of the corporation&rsquo;s outstanding voting stock. These provisions may have
the effect of delaying, deferring or preventing a change in our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Compliance with the reporting requirements
of federal securities laws can be expensive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">We are subject to the
information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of
the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities
and Exchange Commission and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial
expenses in connection with the preparation of registration statements and related documents with respect any offerings of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">Our ability to utilize
our federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue
Code of 1986, as amended, or the Code.&nbsp; The limitations apply if we experience an &ldquo;ownership change&rdquo;, generally
defined as a greater than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year
period.&nbsp;Similar provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously
occurred.&nbsp;If we have experienced an ownership change at any time since our formation, we may already be subject to limitations
on our ability to utilize our existing net operating losses and other tax attributes to offset taxable income. In addition, future
changes in our stock ownership, which may be outside of our control, may trigger an ownership change and, consequently, the limitations
under Sections 382 and 383 of the Code.&nbsp;As a result, if or when we earn net taxable income, our ability to use our pre-change
net operating loss carryforwards and other tax attributes to offset such taxable income may be subject to limitations, which could
adversely affect our future cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left"><B><I>Failure to establish and maintain
adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting
and internal controls requirements for publicly traded companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As a public company,
we operate in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company
responsibilities required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining
corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal
controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts.
We complied with Section 404 at December 31, 2018 and 2017 and while our testing did not reveal any material weaknesses in our
internal controls, subsequent testing by our independent registered public accounting firm may reveal material weaknesses in our
internal controls that we would be required to remediate in a timely manner so as to be able to comply with the requirements of
Section 404 of the Sarbanes-Oxley Act each year. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley
Act in a timely manner each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory
authorities which would require additional financial and management resources and could adversely affect the market price of our
common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations
could be harmed, and investors could lose confidence in our reported financial information.&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Risks Relating to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management team may invest or spend the proceeds of
this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management will have broad discretion
over the use of proceeds from this offering. We currently intend to use the net proceeds from the sale of securities offered by
this prospectus to fund our ongoing pivotal, Phase 3 SIERRA trial for our lead product candidate Iomab-B and progress Phase 1 trials
from our refocused CD33 program to the proof of concept stage. We will also use the proceeds to support our AWE Technology Platform
including our Iomab-ACT program, research and development and general working capital needs. However, our management will have
broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve
our results of operations or enhance the value of our common stock. The failure by management to apply these funds effectively
could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock
to decline and delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Purchasers in this offering will likely experience immediate
and substantial dilution in the book value of their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because the effective public offering price
per share is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial dilution
in the net tangible book value of the common stock you purchase in this offering. After giving effect to the sale by us of 100,833,333&nbsp;shares
of our common stock and our pre-funded warrants to purchase 82,500,001shares of common stock at an effective public offering price
of $0.15 per share of common stock, and after deducting the underwriting discounts and commissions and estimated offering expenses
payable by us, you will suffer immediate and substantial dilution of $0.0523&nbsp; per share in the net tangible book value of
the common stock you purchase in this offering. See &ldquo;Dilution&rdquo; on page S-31 for a more detailed discussion of the dilution
you will incur in connection with this offering. To the extent outstanding stock options or warrants are exercised, there may be
further dilution to new investors. In addition, to the extent we need to raise additional capital in the future, and we issue additional
equity or convertible debt securities, our then existing stockholders may experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is no established public trading market for the
pre-funded warrants being offered in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is no established public trading market
for the pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend
to apply to list the pre-funded warrants on any national securities exchange or other nationally recognized trading system, including
the NYSE American. Without an active market, the liquidity of the pre-funded warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a substantial number of shares of our common
stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales of a substantial number of shares
of our common stock in the public market could occur at any time. These sales, or the perception that such sales may occur, may
adversely impact the price of our common stock, even if there is no relationship between such sales and the performance of our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of April 14, 2020, we had 174,839,536
shares of common stock outstanding, as well as outstanding options to purchase an aggregate of 11,037,551 shares of our common
stock at a weighted average exercise price of $1.19 per share and outstanding warrants to purchase an aggregate of 86,140,575 shares
of our common stock at a weighted average exercise price of $0.69 per share. The exercise of such outstanding options and warrants
may result in further dilution of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>Special
Note Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and accompanying
prospectus and the information incorporated by reference in this prospectus supplement and accompanying prospectus contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which include information relating to future events, future
financial performance, strategies, expectations, competitive environment and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements
should not be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our
management&rsquo;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Important factors that could cause such differences include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">our history of recurring losses and negative cash
flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to
pursue our complete business objectives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">our ability to complete clinical trials as anticipated
and obtain and maintain regulatory approvals for our products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">our ability to adequately protect our intellectual
property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">disputes over ownership of intellectual property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">our dependence on a single manufacturing facility
and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the risk that the data collected from our current
and planned clinical trials may not be sufficient to demonstrate that our products are an attractive alternative to other procedures
and products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">intense competition in our industry, with competitors
having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing
and sales, distribution and personnel resources than we do;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">entry of new competitors and products and potential
technological obsolescence of our products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">loss of a key customer or supplier;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">adverse economic conditions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">adverse federal, state and local government regulation,
in the United States;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">price increases for supplies and components;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">inability to carry out research, development and commercialization
plans; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">loss or retirement of key executives and research
scientists.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we believe that the forward-looking
statements contained herein are reasonable, we can give no assurance that our expectations will be met. All forward-looking statements
contained herein are expressly qualified in their entirety by this cautionary statement and the risk factors beginning on page
S-8 of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this prospectus supplement. Except to the extent required
by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect events or
circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We estimate the net proceeds from this offering
will be approximately $25.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the underwriters exercise their option to
purchase additional securities in full, we estimate the net proceeds from this offering will be approximately $29.1 million, after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently intend to use the net proceeds
from the sale of securities offered by this prospectus to fund our ongoing pivotal, Phase 3 SIERRA trial for our lead product candidate
Iomab-B, advance our Iomab-ACT program for targeted conditioning to proof of concept and progress Phase 1 trials from our refocused
CD33 program to the proof of concept stage. We will also use the proceeds to support our AWE Technology Platform including, research
and development and general working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investors are cautioned, however, that expenditures
may vary substantially from these uses. Investors will be relying on the judgment of our management, who will have broad discretion
regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon
numerous factors, including the amount of cash generated by our operations, the amount of competition and other operational factors.
We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, we evaluate these and
other factors and we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including
the proceeds of this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">a change in development plan or strategy;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the addition of new products or applications;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">technical delays;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">delays or difficulties with our clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">negative results from our clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">difficulty obtaining U.S. Food and Drug Administration
approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">failure to achieve sales as anticipated; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the availability of other sources of cash including
cash flow from operations and new bank debt financing arrangements, if any.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pending other uses, we intend to invest the
proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit or direct or
guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will yield a favorable,
or any, return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you purchase shares of our common stock
(and/or pre-funded warrants) in this offering, you will experience dilution to the extent of the difference between the effective
public offering price per share of common stock in this offering and our as adjusted net tangible book value per share immediately
after this offering. Net tangible book value is total assets minus the sum of liabilities and intangible assets. Net tangible
book value per share is net tangible book value divided by the total number of shares of common stock outstanding. As of September
30, 2019, our net tangible book value was $8.7 million, or approximately $0.053 per share. Dilution with respect to net tangible
book value per share represents the difference between the amount per share or pre-funded warrant paid by purchasers in this offering
and the net tangible book value per share of our common stock immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After giving effect to the sale of 100,833,333
shares of our common stock in this offering at a public offering price of $0.15&nbsp;per share and pre-funded warrants to purchase
82,500,001 shares of common stock in this offering at a public offering price of $0.1499&nbsp;per pre-funded warrant, and after
deducting estimated underwriting fees and estimated offering expenses payable by us, assuming the exercise of all pre-funded warrants
at the exercise price of $0.0001 per share of common stock, our as-adjusted net tangible book value as of September 30, 2019 would
have been approximately $34.0 million , or $0.0977 per share. This represents an immediate increase in net tangible book value
of $0.0447per share to existing stockholders and immediate dilution of $0.0523 per share to purchasers purchasing our securities
in this offering at the public offering price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates the dilution
in net tangible book value per share to new investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective public offering price per share:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.15</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of September 30, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0530</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0447</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.0977</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.0523</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the underwriters exercise their option to purchase additional
shares of common stock in full, our as adjusted net tangible book value will increase to approximately $ 0.1008&nbsp; per share,
representing an increase in net tangible book value of $0.0478 per share, and an immediate dilution of approximately $0.0492 per
share to new investors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing discussion and table do not
take into account further dilution to new investors that could occur upon the exercise of outstanding options or warrants having
a per share exercise price less than the public offering price in this offering. To the extent that we raise additional capital
through the sale of equity or convertible debt securities, the issuance of those securities could result in further dilution to
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The above discussion and table are based
on 164,701,167 shares outstanding as of September 30, 2019 and excludes:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">11,931,801 shares of common stock issuable upon the exercise
of stock options outstanding as of September 30, 2019 under our equity incentive plans, with a weighted average exercise price
of $1.14 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">11,255,569 shares of common stock available for future grants
under our equity incentive plans as of September 30, 2019; and</P>


</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">86,335,713 shares of common stock issuable upon the exercise
of warrants outstanding as of September 30, 2019, with a weighted average exercise price of $0.69 per share.</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>Description
of Securities we are Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The material terms and provisions of our common
stock are described under the caption &ldquo;Description of Capital Stock&rdquo; in the accompanying prospectus beginning on page
11. As of April 20, 2020, we had 175,010,366 shares of our common stock outstanding. Our common stock is listed on the NYSE American
under the&nbsp;symbol &ldquo;ATNM&rdquo;.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Pre-Funded&nbsp;Warrants&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following is a summary of the material terms and provisions of the&nbsp;pre-funded&nbsp;warrants that are being offered hereby.
This summary is subject to and qualified in its entirety by the form of&nbsp;pre-funded&nbsp;warrants, which has been provided
to the investors in this offering and which will be filed with the SEC as an exhibit to a Current Report on Form&nbsp;8-K&nbsp;in
connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement
forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete
description of the terms and conditions of the&nbsp;pre-funded&nbsp;warrants.&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Duration
and Exercise Price</I><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The&nbsp;pre-funded&nbsp;warrants offered
hereby will have an exercise price of $0.0001 per share. The&nbsp;pre-funded&nbsp;warrants will be immediately exercisable and
may be exercised at any time after their original issuance until such&nbsp;pre-funded&nbsp;warrants are exercised in full. The
exercise price and number of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of
share dividends, share splits, reorganizations or similar events affecting our shares of common stock.&nbsp;Pre-funded&nbsp;warrants
will be issued in certificated form only.&nbsp;</P>



<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Exercisability</I><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The&nbsp;pre-funded&nbsp;warrants
will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise
as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s warrants to the
extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common
stock immediately after exercise, except that upon at least 61 days&rsquo; prior notice from the holder to us, the holder may
increase the amount of ownership of outstanding shares of common stock after exercising the holder&rsquo;s&nbsp;pre-funded&nbsp;warrants
up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the&nbsp;pre-funded&nbsp;warrants. Purchasers in this offering may also
elect prior to the issuance of&nbsp;pre-funded&nbsp;warrants to have the initial exercise limitation set at 9.99% of our outstanding
shares of common stock.&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Cashless
Exercise</I><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If,
at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common
stock underlying the pre-funded warrants under the Securities Act of 1933, as amended, or the Securities Act, is not then effective
or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrant.<B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Fundamental
Transactions</I></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event of any fundamental transaction, as described in the&nbsp;pre-funded&nbsp;warrants and generally including any merger
with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification
of our shares of common stock, then upon any subsequent exercise of a&nbsp;pre-funded&nbsp;warrant, the holder will have the right
to receive as alternative consideration, for each share of common stock that would have been issuable upon such exercise immediately
prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation
or of our company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such
transaction by a holder of the number of shares of common stock for which the&nbsp;pre-funded&nbsp;warrant is exercisable immediately
prior to such event.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Transferability</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
accordance with its terms and subject to applicable laws, a&nbsp;pre-funded&nbsp;warrant may be transferred at the option of the
holder upon surrender of the&nbsp;pre-funded&nbsp;warrant to us together with the appropriate instruments of transfer and payment
of funds sufficient to pay any transfer taxes (if applicable).&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Fractional
Shares</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
fractional shares of common stock will be issued upon the exercise of the&nbsp;pre-funded&nbsp;warrants. Rather, the number of
shares of common stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Trading
Market</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
is no established trading market for the&nbsp;pre-funded&nbsp;warrants, and we do not expect a market to develop. We do not intend
to apply for a listing for the pre-funded warrants on any securities exchange or other nationally recognized trading system. Without
an active trading market, the liquidity of the&nbsp;pre-funded&nbsp;warrants will be limited.&nbsp;</FONT></P>


<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Shareholder</I>&nbsp;</FONT></P>

<P STYLE="font: 7pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the&nbsp;pre-funded&nbsp;warrants or by virtue of the holders&rsquo; ownership of shares of common stock,
the holders of&nbsp;pre-funded&nbsp;warrants do not have the rights or privileges of holders of our shares of common stock, including
any voting rights, until such&nbsp;pre-funded&nbsp;warrant holders exercise their warrants.</FONT></P>

<P STYLE="font: 7pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_009"></A><FONT STYLE="text-transform: uppercase"><B>Underwriting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">H.C. Wainwright &amp; Co., LLC is acting
as representative of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement
among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally
and not jointly, to purchase from us, the number of shares of our common stock and pre-funded warrants set forth opposite its
name below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><B>Number
                                         of Shares</B></P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><B>Number
                                         of<BR>
                                         Pre-Funded Warrants</B></P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">H.C. Wainwright &amp; Co., LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">77,916,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">82,500,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Maxim Group LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">JonesTrading Institutional Services LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,166,666</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100,833,333</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">82,500,001</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriting agreement provides that
the obligation of the underwriters to purchase the shares of common stock and pre-funded warrants offered by this prospectus supplement
is subject to certain conditions. The underwriters are obligated to purchase all of the shares of common stock and pre-funded
warrants offered hereby if any of the securities are purchased, other than those shares covered by the option to purchase additional
shares described below.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to indemnify the several
underwriters against certain liabilities, including liabilities under the Securities Act relating to losses or claims resulting
from material misstatements in or omissions from this prospectus supplement, the registration statement of which this prospectus
supplement is a part, certain free writing prospectuses that may be used in the offering and in any marketing materials used in
connection with this offering and to contribute to payments the underwriters may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discounts, Commissions and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The underwriters propose to offer the shares
of common stock and pre-funded warrants pursuant to the underwriting agreement to the public at the applicable public offering
price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess
of $0.00675 per share based on the public offering price per share or pre-funded warrant set forth on the cover page of this prospectus
supplement. After this offering, the public offering price and concession may be changed by the underwriters. No such change shall
change the amount of proceeds to be received by us as set forth on the cover page of this prospectus supplement.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows underwriting discounts
and commissions payable to the underwriters by us in connection with this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Pre-Funded Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total without Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total with Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; padding-bottom: 1.5pt">Public offering price</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0.15</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0.1499</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,491,750</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">31,616,750</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Underwriting discounts and commissions paid by us</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.0105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.0105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,925,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,213,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net proceeds, before expenses, to us</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1395</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1394</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,566,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29,403,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriting agreement provides that
the obligations of the several underwriters to pay for and accept delivery of the shares of common stock (and/or pre-funded warrants)
offered by this prospectus supplement are subject to the approval of certain legal matters by their counsel and to certain other
conditions. The underwriters are obligated to take and pay for all of the shares of common (and/or pre-funded warrants) offered
by this prospectus supplement if any such securities are taken. If an underwriter defaults, the underwriting agreement provides
that the purchase commitments of the non-defaulting underwriters may be increased. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The estimated offering expenses payable
by us, exclusive of the underwriting discounts and commissions, are approximately $0.3 million, which includes legal, accounting
and printing costs and various other fees associated with the registration and listing of our common stock, as well as reimbursement
we have agreed to provide to the representative for certain expenses they incurred in connection with this offering consisting
of (a) up to $100,000 for fees and expenses of legal counsel and other out-of-pocket expenses, (b) $25,000 for non-accountable
expenses and (c) $12,900 for clearing expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option to Purchase Additional Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have granted the underwriters an option to
purchase additional securities. This option, which is exercisable for up to 30 days after the date of this prospectus supplement,
permits the underwriters to purchase up to&nbsp;27,500,000&nbsp;shares of common stock at a public offering price of $0.15 per
share, less underwriting discounts and commissions. If any shares are purchased with this option to purchase additional shares,
the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares
of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares
are being offered.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Sales of Similar Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed with the underwriters, subject to specified
exceptions and until the date that is 90 days after the date of this prospectus supplement not to (i) offer, sell, contract to
sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or
file with the SEC a registration statement under the Securities Act relating to, any shares of our common stock or any securities
that are substantially similar to our common stock, including but not limited to any options or warrants to purchase shares of
our common stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, common
stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition
or filing or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of our common stock, or any such other securities, whether any such transaction described in clause (i) or (ii) above
is to be settled by delivery of our common stock or such other securities, in cash or otherwise, without the prior written consent
of the representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our directors and executive officers have
agreed with the underwriters, subject to specified exceptions, not to (i) offer, pledge, announce the intention to sell, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of our common
stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive our common stock
(including without limitation, our common stock which may be deemed to be beneficially owned in accordance with the rules and regulations
of the SEC and securities which may be issued upon exercise of a stock option or warrant), whether now owned or hereafter acquired,
or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of our common stock, whether any such transaction is to be settled by delivery of our common stock or such other securities, in
cash or otherwise. These restrictions will apply through and including the date that is 90 days after the date of this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have also agreed to a restriction on the issuance of any
variable priced securities for 12 months following the closing of this offering, except that we may use our existing at-the-market
offering facility and/or may enter into new at-the-market offering facilities through a registered broker-dealer following the
90-day anniversary of the closing date of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on the NYSE American
under the symbol &ldquo;ATNM.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price Stabilization, Short Positions and Penalty Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The underwriters
may engage in syndicate covering transactions, stabilizing transactions and penalty bids or purchases for the purpose of pegging,
fixing <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or maintaining the price of our shares of common
stock:</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
    covering transactions involve purchases of securities in the open market after the distribution has been completed in order
    to cover syndicate short positions. Such a naked short position would be closed out by buying securities in the open market.
    A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure
    on the price of the securities in the open market after pricing that could adversely affect investors who purchase in the
    offering.</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specific maximum.</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt/12pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by
    the syndicate member are purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
syndicate covering transactions, stabilizing transactions and penalty bids may have the effect of raising or maintaining the market
prices of our securities or preventing or retarding a decline in the market prices of our securities. As a result, the price of
our shares of common stock may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters
make any representation or prediction as to the effect that the transactions described above may have on the price of our shares
of common stock. These transactions may be effected on the NYSE American, in the over-the-counter market or on any other trading
market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the prices of our securities. In addition, neither we nor the underwriters make any representation
that the underwriters will engage in these transactions or that any transactions, once commenced, will not be discontinued without
notice.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriters, if any, participating in
this offering and the underwriters may distribute prospectuses electronically. Other than the prospectus in electronic format,
the information on these websites is not part of this prospectus supplement or the registration statement of which this prospectus
supplement forms a part, has not been approved or endorsed by us or the underwriters, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriters and their respective affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage
activities. Certain of the underwriters and their affiliates may engage in from time to time in the future certain investment banking
and other commercial dealings in the ordinary course of business with us or our affiliates, for which they have received and may
continue to receive customary fees and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ordinary course of their various business
activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt
and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account
and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments
of the issuer. The underwriters and their respective affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that
they acquire, long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selling Restrictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Resale Restrictions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The distribution of shares of our common
stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis
exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where
trades of these securities are made. Any resale of shares of our common stock in Canada must be made under applicable securities
laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory
exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are
advised to seek legal advice prior to any resale of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Representations of Canadian Purchasers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By purchasing shares of our common stock
in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the purchaser is entitled under applicable provincial
securities laws to purchase the shares of common stock without the benefit of a prospectus qualified under those securities laws
as it is an &ldquo;accredited investor&rdquo; as defined under National Instrument 45-106&mdash;Prospectus Exemptions,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the purchaser is a &ldquo;permitted client&rdquo;
as defined in National Instrument 31-103&mdash;Registration Requirements, Exemptions and Ongoing Registrant Obligations,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">where required by law, the purchaser is purchasing
as principal and not as agent, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">the purchaser has reviewed the text above under Resale
Restrictions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conflicts of Interest</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Canadian purchasers are hereby notified that
the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105 &mdash;
<I>Underwriting Conflicts </I>from having to provide certain conflict of interest disclosure in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Statutory Rights of Action</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum (including
any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages
are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province
or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation
of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Enforcement of Legal Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our directors and officers as well
as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to
effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of
those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those
persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Taxation and Eligibility for Investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Canadian purchasers of shares of our common
stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of common
stock in their particular circumstances and about the eligibility of shares of our common stock for investment by the purchaser
under relevant Canadian legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>European Economic Area</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In relation to each Member State of the European
Economic Area that has implemented the Prospectus Directive, each referred to as a Relevant Member State, an offer to the public
of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant
Member State of any shares of our common stock may be made at any time under the following exemptions under the Prospectus Directive,
if they have been implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">to any legal entity which is a &ldquo;qualified investor&rdquo;
as defined in the Prospectus Directive;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">to fewer than 150 natural or legal persons (other
than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters for
any such offer; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">in any other circumstances falling within Article
3(2) of the Prospectus Directive,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided that no such offer of shares of our common stock shall
result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the purposes of this provision, the expression
an &ldquo;offer to the public&rdquo; in relation to any shares of our common stock in any Relevant Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered
so as to enable an investor to decide to purchase any shares of our common stock, as the same may be varied in that Relevant Member
State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression &lsquo;&lsquo;Prospectus
Directive&rsquo;&rsquo; means Directive 2003/71/EC (and amendments thereto, including by Directive 2010/73/EU) and includes any
relevant implementing measure in each Relevant Member State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each underwriter has represented and agreed
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">it has not made or will not make an offer of shares
of our common stock to the public in the United Kingdom within the meaning of section 102B of the Financial Services and Markets
Act 2000 (as amended) (FSMA) except to legal entities which are authorized or regulated to operate in the financial markets or,
if not so authorized or regulated, whose corporate purpose is solely to invest in securities or otherwise in circumstances which
do not require the publication by us of a prospectus pursuant to the Prospectus Rules of the Financial Services Authority;</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">it has only communicated or caused to be communicated
and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the
meaning of section 21 of FSMA) to persons who have professional experience in matters relating to investments falling within Article
19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or in circumstances in which section 21
of FSMA does not apply to us; and</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United
Kingdom.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No securities have been offered or sold,
and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &lsquo;&lsquo;professional investors&rsquo;&rsquo;
as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a &lsquo;&lsquo;prospectus&rsquo;&rsquo; as defined in the Companies Ordinance
(Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32)
of Hong Kong. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in
the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or
the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws
of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong
or only to &lsquo;&lsquo;professional investors&rsquo;&rsquo; as defined in the Securities and Futures Ordinance (Cap. 571) of
Hong Kong and any rules made under that Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus has not been registered with
the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong,
and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities
will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers
of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been
offered any securities in circumstances that contravene any such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Singapore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus has not been, and will not
be, registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock may not
be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as
defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore (the &ldquo;SFA&rdquo;)) pursuant to Section
274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1), or any person pursuant
to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and
in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions
set forth in the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Where the common stock is subscribed or purchased
under Section 275 of the SFA by a relevant person which is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">a corporation (which is not an accredited investor
(as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which
is owned by one or more individuals, each of whom is an accredited investor; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">a trust (where the trustee is not an accredited investor)
whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">securities (as defined in Section 239(1) of the SFA) of that
corporation or the beneficiaries&rsquo; rights and interest (howsoever described) in that trust shall not be transferred within
six months after that corporation or that trust has acquired the common stock pursuant to an offer made under Section 275 of the
SFA except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">to an institutional investor pursuant to Section 274
of the SFA or to a relevant person pursuant to Section 275(1) of the SFA, or to any person arising from an offer referred to in
Section 275(1A) or Section 276(4)(i)(B) of the SFA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">where no consideration is or will be given for the
transfer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">where the transfer is by operation of law;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: left">as specified in Section 276(7) of the SFA; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: left">as specified in Regulation 32 of the Securities and
Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The shares of common stock may not be publicly
offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange or regulated
trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27
ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither
this document nor any other offering or marketing material relating to the shares of common stock or the offering may be publicly
distributed or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither this document nor any other offering
or marketing material relating to the offering, or the shares of common stock have been or will be filed with or approved by any
Swiss regulatory authority. In particular, this document will not be filed with, and the offer of common stock will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of common stock has not been and will not be authorized
under the Swiss Federal Act on Collective Investment Schemes, or CISA. Accordingly, no public distribution, offering or advertising,
as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA,
its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers
of interests in collective investment schemes under CISA does not extend to acquirers of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United Arab Emirates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offering has not been reviewed, approved
or licensed by the Central Bank of the United Arab Emirates (the &ldquo;UAE&rdquo;), the Emirates Securities and Commodities Authority
of the UAE (the &ldquo;SCA&rdquo;) and/or any other relevant licensing authority in the UAE including any licensing authority incorporated
under the laws and regulations of any of the free zones established and operating in the territory of the UAE (the &ldquo;Free
Zones&rdquo;), in particular the Dubai Financial Services Authority (the &ldquo;DFSA&rdquo;), a regulatory authority of the Dubai
International Financial Centre the (&ldquo;DIFC&rdquo;) or the Financial Services Regulatory Authority (the &ldquo;FSRA&rdquo;),
a regulatory authority of Abu Dhabi Global Market (&ldquo;ADGM&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offering is not intended to, and does
not, constitute an offer, sale or delivery of shares or other securities under the laws of the UAE. The common stock has not been
and will not be registered with or licensed by the SCA or with the UAE Central Bank, the Dubai Financial Market, the Abu Dhabi
Securities Exchange or with any other UAE regulatory authority or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The issue and/or sale of the common stock
has not been approved or licensed by the SCA, the UAE Central Bank or any other relevant licensing authority in the UAE, and does
not constitute a public offer of securities in the UAE, DIFC, ADGM and/or any other Free Zone in accordance with the Commercial
Companies Law, Federal Law No 2 of 2015 (as amended), the Markets Rules of the DFSA, (the &ldquo;DFSA Markets Rules&rdquo;), the
Markets Rules of the FSRA (the &ldquo;FSRA Markets Rules&rdquo;) and/or Nasdaq Dubai Listing Rules or under any other law of the
UAE. The common stock may not be offered to the public in the UAE and/or any of the Free Zones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No marketing or promotion of the common stock
has been or will be made from within the UAE and no sale of or subscription for the common stock may or will be consummated within
the UAE. It should not be assumed that Primo Water Corporation, Primo Water Corporation&rsquo;s advisors, their advisors or any
other person is a licensed broker, dealer or investment adviser under the laws of the UAE or that they advise as to the appropriateness
of investing in or purchasing or selling securities or other financial products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offering is not intended to constitute
a financial promotion, an offer, sale or delivery of shares or other securities under the DIFC Markets Law (DIFC Law No. 1 of 2012,
as amended) (the &ldquo;Markets Law&rdquo;), the DFSA Markets Rules, the Collective Investment Law 2010 (DIFC Law No. 2 of 2010)
(the &ldquo;Collective Investment Law&rdquo;), the ADGM Financial Services and Markets Regulations 2015 (the &ldquo;FSMR&rdquo;),
the FSRA Markets Rules, the Funds Rules of the FSRA (&ldquo;FSRA Funds Rules&rdquo;), or any other laws and regulations of the
DIFC, the DFSA, ADGM or the FSRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offering and the issue or transfer of
any securities related to it have not been approved or licensed by the DFSA, and do not constitute an offer of securities in the
DIFC in accordance with the Markets Law or the DFSA Markets Rules or the Collective Investment Law or any other laws and regulations
of the DIFC or the DFSA. This offering and the issue or transfer of any securities related to it have not been approved or licensed
by the FSRA, and do not constitute an offer of securities in ADGM in accordance with the FSMR or the FSRA Markets Rules or the
FSRA Funds Rules or any other laws and regulations of ADGM or the FSRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notice to Prospective Investors in Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The securities offered by this prospectus
supplement and the accompanying prospectus have not been approved or disapproved by the Israeli Securities Authority (the &lsquo;&lsquo;ISA&rsquo;&rsquo;),
nor have such securities been registered for sale in Israel. The ISA has not issued permits, approvals or licenses in connection
with the offering or publishing this prospectus supplement and the accompanying prospectus; nor has it authenticated the details
included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being
offered. The ordinary shares will not be offered or sold, directly or indirectly, to the public in Israel, except that the underwriters
may offer and sell such shares to Israeli investors who qualify, in accordance with the Israeli Securities Law as &lsquo;&lsquo;qualified
investors&rsquo;&rsquo; (as defined in the First Appendix to the Israeli Securities Law) and completed and signed a questionnaire
regarding such qualification and delivered it to the underwriter. Any resale in Israel, directly or indirectly, to the public of
the securities offered by this prospectus supplement and the accompanying prospectus is subject to restrictions on transferability
and must be effected only in compliance with the Israeli securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_010"></A><FONT STYLE="text-transform: uppercase"><B>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities offered by
this prospectus will be passed upon for us by The Matt Law Firm, PLLC, Utica, New York. Certain legal matters will be passed upon
for the underwriters by Lowenstein Sandler LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><FONT STYLE="text-transform: uppercase"><B>Experts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements incorporated in
this prospectus supplement by reference to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 has been
so incorporated in reliance on the report of Marcum LLP, an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase"><B>Where
You Can Find More Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the informational requirements
of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current reports, proxy
statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains
a website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the Securities and Exchange Commission. The address of the Securities and Exchange Commission&rsquo;s website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We make available free of charge on or through
our website at <I>www.actiniumpharma.com</I>, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it
to the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the Securities and Exchange
Commission a registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities.
The registration statement, including the attached exhibits, contains additional relevant information about us and the securities.
This prospectus supplement does not contain all of the information set forth in the registration statement. You can obtain a copy
of the registration statement, at prescribed rates, from the Securities and Exchange Commission at the address listed above, or
for free at <I>www.sec.gov</I>. The registration statement and the documents referred to below under &ldquo;Incorporation of Certain
Information By Reference&rdquo; are also available on our website, <I>www.actiniumpharma.com</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not incorporated by reference into
this prospectus supplement the information on our website, and you should not consider it to be a part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_013"></A><FONT STYLE="text-transform: uppercase"><B>Incorporation
of Certain Information by Reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Securities and Exchange Commission allows
us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can disclose important
information to you by referring you to those documents. The information we incorporate by reference is an important part of this
prospectus supplement, and later information that we file with the Securities and Exchange Commission will automatically update
and supersede this information. We incorporate by reference the documents listed below and any future documents (excluding information
furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the Securities and Exchange Commission pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus supplement
and prior to the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018_actiniumpharma.htm">Form 10-K</A> for the fiscal year ended December
31, 2018, filed with the Securities and Exchange Commission on March 15, 2019;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2019, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019008291/f10q0319_actiniumpharma.htm">May 10, 2019</A>; our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2019, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019015171/f10q0619_actiniumpharma.htm">August 9, 2019</A>; and our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2019, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019022937/f10q0919_actiniumpharma.htm">November 12, 2019</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the portions of our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019024628/def14a1119_actiniumpharma.htm">Schedule 14A</A> filed with the SEC on November 25, 201</FONT><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">9</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">that are deemed &ldquo;filed&rdquo; with the SEC under the Exchange Act;</FONT></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Our Current Reports on Forms 8-K filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019003990/f8k030619_actiniumpharma.htm">March
                                                                                      12, 2019</A>. <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/f8k041819_actiniumpharma.htm">April
                                                                                      18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019010336/f8k060719_actiniumpharm.htm">June 7, 2019</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019024626/f8k112519_actiniumpharm.htm">November
                                                                                      25, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019025210/f8k120219_actiniumpharma.htm">December 3, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019026593/f8k121819_actiniumpharma.htm">December
                                                                                      19, 2019</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020007702/ea119813-8k_actiniumpharma.htm">March 27, 2020</A>; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">The description of our common stock, which is contained
in our Form 8-K/A, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013000373/f8k122812a2_cactusventures.htm">January 28, 2013</A>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All filings filed by us pursuant to the Securities
Exchange Act of 1934, as amended, after the date of the initial filing of this registration statement and prior to the effectiveness
of such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also be deemed
to be incorporated by reference into the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information incorporated
by reference or provided in this prospectus supplement. We have not authorized anyone else to provide you with different information.
You should not assume that the information in this prospectus supplement is accurate as of any date other than the date of this
prospectus supplement or the date of the documents incorporated by reference in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will provide without charge to each person
to whom a copy of this prospectus supplement is delivered, upon written or oral request, a copy of any or all of the information
that has been incorporated by reference in this prospectus supplement but not delivered with this prospectus supplement (other
than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus supplement).
Any such request should be addressed to us at: 275 Madison Avenue, 7th Floor, New York, New York 10016, Attention: Steve O&rsquo;Loughlin,
Vice President, Finance and Corporate Development, or made by phone at (646) 677-3870. You may also access the documents incorporated
by reference in this prospectus supplement through our website at <I>www.actiniumpharma.com</I>. Except for the specific incorporated
documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus
supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">ACTINIUM
PHARMACEUTICALS, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">$200,000,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Preferred
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Debt
Securities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Purchase
Contracts&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Units</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the
offering, any combination of the securities described in this prospectus, up to an aggregate amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update
or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement
as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of
the securities offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These securities may be offered and sold in
the same offering or in separate offerings; to or through underwriters, dealers and agents; or directly to purchasers. The names
of any underwriters, dealers or agents involved in the sale of our securities, their compensation and any over-allotment options
held by them will be described in the applicable prospectus supplement. See &ldquo;Plan of Distribution.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is presently traded on the NYSE American under the symbol &ldquo;ATNM.&rdquo; On October 23, 2017, the last reported
sale price of our common stock was $0.72 per share. We recommend that you obtain current market quotations for our common stock
prior to making an investment decision. We will provide information in any applicable prospectus supplement regarding any listing
of securities other than shares of our common stock on any securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should carefully read this prospectus, any prospectus supplement relating to any specific offering of securities, and all information
incorporated by reference herein and therein.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo;
beginning on page 8 and in the documents incorporated by reference into this prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is October 24, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_001">ABOUT THIS PROSPECTUS</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_002">PROSPECTUS SUMMARY</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_003">RISK FACTORS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_004">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_005">USE OF PROCEEDS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_006">DESCRIPTION OF CAPITAL STOCK</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_007">DESCRIPTION OF DEBT SECURITIES</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_008">DESCRIPTION OF WARRANTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_009">DESCRIPTION OF RIGHTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_010">DESCRIPTION OF PURCHASE CONTRACTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_011">DESCRIPTION OF UNITS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_012">PLAN OF DISTRIBUTION</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_013">LEGAL MATTERS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_014">EXPERTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_015">WHERE YOU CAN FIND MORE INFORMATION</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#pa_016">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">33</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo;
registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in
this prospectus in one or more offerings up to a total amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may
also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent, information
in this prospectus is superseded by the information in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities
offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the
offering of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or
issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make
any representations in connection with this offering other than those contained or incorporated by reference in this prospectus,
any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described
herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized
by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an
offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person
to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration
statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement,
including its exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the
documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus,
before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free
writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated
by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to
the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the
information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only
as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our
business, financial condition, results of operations and prospects may have changed since that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="pa_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does
not contain all of the information you should consider before investing in our securities. You should carefully read the prospectus,
the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety
before investing in our securities, including the information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and
the documents incorporated by reference and our financial statements and notes thereto that are incorporated by reference in this
prospectus. As used in this prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo;
&ldquo;us,&rdquo; or &ldquo;the Company&rdquo; refer to Actinium Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries
taken as a whole.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for safer myeloablation
and conditioning of the bone marrow prior to a bone marrow transplant, or BMT, and for the targeting and killing of cancer cells.
We are currently conducting clinical trials for our three product candidates, Iomab-B, Actimab-A and Actimab-M, as well as performing
research on other potential drug candidates utilizing our proprietary alpha-particle technology platform. Our most advanced product
candidate, Iomab-B, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131, or I-131. We are currently conducting
a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a BMT for patients with relapsed
or refractory acute myeloid leukemia (AML) age 55 and older. A BMT is a potentially curative treatment option for patients with
AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Upon successful
completion of our Phase 3 clinical trial for Iomab-B we intend to submit for marketing approval in the United States and European
Union. Our most advanced alpha-particle based therapy, Actimab-A, is an anti-CD33 monoclonal antibody conjugated with the alpha-particle
actinium-225 (Ac-225). Actimab-A is currently in a Phase 2 clinical trial for patients over the age of 60 who are newly diagnosed
with AML and ineligible for standard induction chemotherapy. Actimab-M, our third product candidate, is the same anti-CD33 monoclonal
antibody conjugated to Ac-225 but a different dose and dosing regimen. Actimab-M, is being studied in a Phase 1 trial for patients
with refractory multiple myeloma. We expect our alpha-particle technology platform will generate additional drug candidates that
we will progress in clinical trials ourselves and or out-license. We intend to develop a number of products for numerous types
of cancer and derive revenue from partnering relationships worldwide and/or direct sales of our products primarily in the United
States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2015, we announced that the U.S. Food and Drug Administration, or FDA, cleared our IND filing for Iomab-B. In June 2016,
we announced the pivotal Phase 3 clinical trial for Iomab-B was initiated, and assuming that the trial meets its end points, it
will form the basis for a Biologics Licensing Application (BLA). We established an agreement with the FDA that the path to a BLA
submission would include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm, randomized,
controlled, multicenter trial will be patients with relapsed or refractory AML over the age of 55. The trial size was set at 150
patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as
a complete remission lasting at least six months and the secondary endpoint will be overall survival at one year. We believe there
are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard
of care. Iomab-B has completed several physicians-sponsored clinical trials examining its potential as a myeloconditioning regimen
prior to BMT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of
these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for BMTs by expanding
the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory
interval for BMT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, we initiated a Phase 2 clinical trial for Actimab-A. This Phase 2 clinical trial is a multicenter, open-label
study that will enroll 53 patients. Patients will receive 2.0 &micro;Ci/kg/fractionated dose of Actimab-A via two injections
given at day 1 and day 7. The Phase 2 trial is designed to evaluate complete response rates at up to day 42 after Actimab-A
administration, including complete remission (CR), complete remission with incomplete platelet recovery, CRp, or complete
remission with incomplete blood count recovery, or CRi. A formal interim analysis is scheduled for 31 patients, which is
expected by the end of 2017. The Phase 2 clinical trial includes peripheral blast burden as an inclusion criteria and in
patients with high peripheral blast, or PB, burden, the use of Hydroxyurea will be mandated with the goal of bringing
peripheral blasts below 200/&micro;L, which we identified from two previously complete Phase 1 clinical trials totaling 38
patients. In addition, the use of granulocyte colony-stimulating factors, or GCSF, will be mandated. Low dose cytarabine has
been eliminated from the protocol and the Phase 2 clinical trial will evaluate Actimab-A as a monotherapy. The secondary
endpoint of the Phase 2 clinical trial will be overall survival.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, we initiated a Phase 1 investigator initiated clinical trial to study Actimab-M in multiple myeloma. Multiple myeloma
is a cancer of plasma cells that is currently incurable. The Phase 1 trial will enroll up to 12 patients with relapsed or refractory
multiple myeloma who have positive CD33 expression. This Phase 1 study is designed as a dose escalation study intended to assess
safety, establish maximum tolerable dose, or MTD, and assess efficacy. Patients will be administered Actimab-M on day 1 at an
initial dose of 0.5 &micro;Ci/kg and then assessed at day 42 for safety and efficacy. The dose can be increased to 1.0 &micro;Ci/kg
or reduced to 0.25 &micro;Ci/kg based on safety assessment that will evaluate dose limiting toxicities, or DLTs. Patients may
receive up to eight cycles of therapy, but in no event will cumulative administration exceed 4.0 &micro;Ci/kg of Actimab-M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to develop our most advanced clinical stage candidate, Iomab-B, through approval and if these efforts are successful, we
may elect to commercialize Iomab-B on our own or with a partner in the United States and/or outside of the United States to out-license
the rights to develop and commercialize the product to a strategic partner. We intend to develop Actimab-A and Actimab-M through
Phase 2 proof of concept human clinical trial, a trial designed to provide data on the drug&rsquo;s efficacy, and we will most
likely seek to enter into strategic partnerships whereby the strategic partner(s) co-fund(s) further human clinical trials of
the drug that are needed to obtain regulatory approvals for commercial sale within and outside of the United States. In parallel,
we intend to identify and begin initial human trials with additional Ac-225 based product candidates in other cancer indications.
We intend to retain marketing rights for our products in the United States whenever possible and out-license marketing rights
to our partners for the rest of the world. We may also seek to in-license other applicable opportunities should such technology
become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Market
Opportunity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete in the marketplace for cancer treatments estimated to reach over $83 billion in 2016 sales, according to &ldquo;The Global
Use of Medicines: Outlook Through 2016 Report by the IMS Institute for Healthcare Informatics, July 2012.&rdquo; While surgery,
radiation and chemotherapy remain staple treatments for cancer, their use is limited by the fact that they often cause substantial
damage to normal cells. On the other hand, targeted monoclonal antibody therapies exert most or all of their effect directly on
cancer cells, but often lack sufficient killing power to eradicate all cancer cells with just the antibody. A new approach for
treating cancer is to combine the precision of antibody-based targeting agents with the killing power of radiation or chemotherapy
by attaching powerful killing agents to precise molecular carriers called monoclonal antibodies, or mAb. We use mAbs labeled with
radioisotopes to deliver potent doses of radiation directly to cancer cells while sparing healthy tissues. The radioisotopes we
use are the alpha emitter Ac-225 and the beta emitter I-131. I-131 is among the best-known and well-characterized radioisotopes.
It is used very successfully in treatment of papillary and follicular thyroid cancer as well as other thyroid conditions. It is
also attached to a monoclonal antibody in treatment of Non-Hodgkin&rsquo;s Lymphoma, or NHL, and is also used experimentally with
different carriers in other cancers. Ac-225 has many unique properties and we believe we are a leader in developing this alpha
emitter for clinical applications using our proprietary alpha-particle technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most advanced products are Iomab-B, I-131 labeled anti-CD45 mAb for myeloablation of relapsed or refractory AML patients
prior to a BMT and Actimab-A, Ac-225 conjugated to an anti-CD33 mAb for treatment of newly diagnosed AML, in patients
ineligible for currently approved therapies. We recently began clinical development of Actimab-M, Ac-225 conjugated to an
anti-CD33 mAb for the treatment of patients with refractory multiple myeloma.Iomab-B offers a potentially curative treatment
for these patients, most of whom do not survive beyond one year after being diagnosed with this condition. Iomab-B has also
demonstrated efficacy in BMT preparation for other blood cancer indications, including myelodysplastic syndrome, or MDS,
acute lymphoblastic leukemia, or ALL, Hodgkin&rsquo;s Lymphoma, multiple myeloma and NHL. These are all follow-on indications
for which Iomab-B can be developed and it is our intention to explore these opportunities at a future date. We believe the
aggregate worldwide market potential for the treatment of AML, MDS, ALL, Hodgkin&rsquo;s Lymphoma, multiple myeloma and NHL
is approximately $4.1 billion.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2015, we announced that the FDA cleared our IND filing for Iomab-B, and that we proceeded with a pivotal, Phase 3 clinical
trial. We anticipate the Phase 3, controlled, randomized, pivotal trial will complete enrollment of patients by 2018 and assuming
that the trial meets its endpoints, it will form the basis for a BLA. We, in our recently approved IND filing, established an
agreement with the FDA that the path to a BLA submission would include a single, pivotal Phase 3 clinical study if it is successful.
The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed AML patients over the
age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial
is durable complete remission, defined as a complete remission lasting at least six months and the secondary endpoint will be
overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population
and there is no defined standard of care. Iomab-B has completed several physicians sponsored clinical trials examining its potential
as a conditioning regimen prior to BMT in various blood cancers, including the Phase 1/2 clinical trial in relapsed and/or refractory
AML patients. The results of these clinical trials in over 300 patients have demonstrated the potential of Iomab-B to create a
new treatment paradigm for BMTs by: expanding the pool to ineligible patients who do not have any viable treatment options currently;
enabling a shorter and safer preparatory interval for BMT; reducing post-transplant complications; and showing a clear survival
benefit including curative potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
potential product opportunities in which significant preclinical work is being undertaken include metastatic colorectal cancer,
metastatic prostate cancer and antiangiogenesis, which reduces the blood supply to solid tumors. We believe the worldwide market
potential for the treatment of metastatic colorectal cancer is approximately $4.8 billion, and we believe the worldwide market
potential for the treatment of metastatic prostate cancer is approximately $6.0 billion. We also believe the worldwide market
potential for the treatment of Glioblastoma Multiforme, a potential indication based on an antiangiogenesis approach, is approximately
$1.1 billion. We estimate the market potential for these indications based on company research, published rates of disease incidence
and company calculations based on costs of currently used therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our biggest market opportunity lies in the applicability of our alpha-particle technology platform to a wide variety
of cancer indications. A broad range of solid and blood borne cancers can be potentially targeted by mAbs to enable treatment
with the alpha-particle technology. We believe that our alpha-particle technology could potentially be applied to mAbs that are
already approved by the FDA to create more efficacious and/or safer drugs (&ldquo;biobetters&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2016, the FDA granted orphan drug designation for Iomab-B and in October 2016, the European Medicines Agency, or EMA, granted
orphan designation in the European Union, or EU, for Iomab-B. In November 2014, the FDA granted orphan-drug designation for Actimab-A
and in May 2017 the EMA granted orphan designation in the EU for Actimab-A. The FDA, through its Office of Orphan Products Development,
grants orphan status to drugs and biologic products that are intended for the safe and effective treatment, diagnosis or prevention
of rare diseases or disorders that affect fewer than 200,000 people in the United States. Orphan drug designation provides a drug
developer with certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately
received for the designated indication; potential tax credits on United States clinical trials; eligibility for orphan drug grants;
and waiver of certain administrative fees. The EMA, through its Committee for Orphan Medicinal Products, or COMP, examines applications
for orphan designation. To qualify for orphan designation, the prevalence of the condition must be less than 5 in 10,000, it must
be life-threatening or chronically debilitating and there must be no satisfactory method of treating the condition. Sponsors who
obtain orphan designation receive numerous incentives including protocol assistance, a reduction or waving of fees and 10 years
of market exclusivity should the therapy be approved.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iomab-B
is our lead product candidate currently in a pivotal Phase 3 multicenter clinical trial. It consists of the anti-CD45 monoclonal
antibody BC8 and beta emitting radioisotope iodine 131 (I-131). The indication for that trial is bone marrow conditioning for
BMT in patients with relapsed and refractory AML over the age of 55.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
Iomab-B clinical trials leading to the Phase 3 trial included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: top">Indications</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: center">N</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: center">Key Findings</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 28%; text-align: left">AML, MDS, ALL (adult)</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 28%; text-align: left">34</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 42%; text-align: left">&ndash;7/34 patients with median disease free state (DFS) of 17 years.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;18/34 patients in remission at day 80</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">AML &gt;1st remission (adult)</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">23</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;15/23 in remission at day 28</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">AML 1st remission (age 16-50)</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">43</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;23/43 DFS from 5-16 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;30/43 in remission at day 28</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;33/43 in remission at day 80</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">High-risk MDS, advanced AML</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">68 in dose escalation study</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;CR (complete remission) in all patients</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">(age 50+)</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">31 treated at MTD</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;1 yr survival ~40% for all patients</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;1 yr survival ~45% for pts treated at MTD maximum tolerated dose)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">High-risk MDS, AML (age 18&ndash;50)</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">14 in dose escalation</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">All patients achieved full donor chimerism by day 28 post-transplant</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">High-risk MDS, AML <BR> &ndash;haploidentical donors (adult)</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">8 in dose escalation</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&ndash;6/8 treated patients achieved CR by day 28 &ndash;8/8 patients 100% donor chimerism by day 28</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing
Iomab-B clinical trials include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold; text-align: center">Indications</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Phase</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Relapsed and refractory Hodgkin Lymphoma and NHL (adult)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Phase 1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Advanced AML, ALL and MDS (adult)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Phase 2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">AML 1st remission (age 16-50)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Phase 2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">High-risk MDS, advanced AML (age 16-50)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Phase 2</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are additional ongoing clinical trials with BC8 antibody labeled with yttrium 90 (Y-90).</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
3 Iomab-B clinical trial:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained FDA&rsquo;s comment and guidance on the Iomab-B Phase 3 clinical trial design, and the FDA identified the following design
features as generally acceptable, dependent on the results of the trial:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Single
pivotal study, pending trial results;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
population: refractory AML patients age of 55 and older, where refractory is defined as either primary failure to achieve a complete
remission after 2 cycles of induction therapy; relapsed after 6 months in complete remission; second or higher relapse; or relapsed
disease not responding to intensive salvage therapy;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
arms: study arm and control arm with physician&rsquo;s choice of conventional care with curative intent; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
size: 150 patients total (75 patients per arm).</FONT></TD>
</TR></TABLE>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actimab-A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actimab-A
is currently in the Phase 2 portion of a multicenter Phase 1/2 clinical trial in AML. It consists of the anti-CD33 monoclonal
antibody Lintuzumab and alpha emitting radioisotope actinium 225 (Ac-225). The indication in the ongoing trial is patients newly
diagnosed with AML over the age of 60 that are ineligible for standard induction chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
clinical trials leading to this trial included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1 clinical trial with Bismab-A, the first generation product consisting of the same anti-CD33 monoclonal antibody Lintuzumab and
Bi-213 alpha emitter, a daughter of Ac-225;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1/2 clinical trial with Bismab-A, the first generation product consisting of the same monoclonal antibody Lintuzumab and Bi-213
alpha emitter, a daughter of Ac-225; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
escalating pilot Phase 1 clinical trial with Actimab-A, the current product consisting of the Lintuzumab monoclonal antibody and
Ac-225 alpha emitter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
Actimab-A related clinical trials outcomes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 arm of the Bismab-A drug study has shown signs of the drug&rsquo;s efficacy and safety, including reduction in peripheral
blast counts and complete responses in some patients. Bi-213 is a daughter, i.e., product of the degradation of Ac-225, with cancer
cell killing properties similar to Ac-225 but is less potent. The Phase 1 Actimab-A trial at MSKCC with a single-dose administration
of Actimab-A showed elimination of leukemia cells from blood in 67% of all evaluable patients who received a full dose and in
83% of those treated at dose levels above 0.5 microcuries per kilogram (&micro;Ci/kg), and eradication of leukemia cells in both
blood and bone marrow in 20% of all evaluable patients and 25% of those treated at dose levels above 0.5 &micro;Ci/kg. Maximum
tolerated single dose in this trial was established at 3 &micro;Ci/kg.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
potency means that a relatively low amount of drug is needed to produce a given effect. In preclinical and Phase 1 clinical studies,
Actimab-A (<SUP>225</SUP>Ac-lintuzumab) has demonstrated at least 500-1000 times higher potency than the first-generation predecessor
(<SUP>213</SUP>Bi-lintuzumab) upon which it is based. This difference is due to intrinsic physicochemical properties of Actimab-A
that were first established <I>in vitro</I>, in which Actimab-A killed multiple cell lines at doses at least 1000 times lower
(based on LD50 values) than Bismab-A analogs. Key factors in Actimab-A&rsquo;s higher potency are the yield of 4 alpha-emitting
isotopes per <SUP>225</SUP>Ac (compared to 1 alpha decay for bismuth 213) and much longer half-life (10 day for <SUP>225</SUP>Ac
vs 46 minutes for <SUP>213</SUP>Bi).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical animal models, doses in the nanocurie range prolonged survival. In humans, Actimab-A was previously studied in a Phase
I monotherapy trial of relapsed or refractory AML patients at MSKCC. Dose levels in that study re-confirmed the substantially
higher potency of Actimab-A, as compared to equivalent dosing of the first-generation Bismab-A (<SUP>213</SUP>Bi-lintuzumab) construct,
which had nevertheless established safety and efficacy in a Phase 1/2 trial in high-risk AML with cytoreduction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sources:
Jurcic JG. Targeted Alpha-Particle Immunotherapy with Bismuth-213 and Actinium-225 for Acute Myeloid Leukemia. J. Postgrad Med
Edu Res 2013, 47(1):14-17; ; JG Jurcic et al, Phase 1 Trial of the Targeted Alpha- Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab
in Acute Myeloid Leukemia (AML) J Clin Oncol 29:2011 (suppl, abstr 6516); McDevitt MR et al, &ldquo;Tumor Therapy with Targeted
Atomic Nanogenerators&rdquo; Science 2001, 294:1537&mdash;1540; Rosenblat TL et al, &ldquo;Sequential cytarabine and alpha-particle
immunotherapy with bismuth- 213-lintuzumab (HuM195) for acute myeloid leukemia&rdquo; Clin Cancer Res. 2010, 16(21):5303-5311;
Jurcic JG et al. &ldquo;Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid
Leukemia (AML)&rdquo; Blood (ASH Meeting Abstracts) 2012.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing
Actimab-A trial:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed the Phase 1 portion of our first company sponsored Phase 1/2 multi-center trial with fractionated (two) doses
of Actimab-A, for the treatment of patients newly diagnosed with AML over the age of 60. Actimab-A consists of an anti-CD33
monoclonal antibody (HuM195, also known as Lintuzumab) and the </FONT>actinium 225 radioactive isotope attached to it.
Results from the Phase 1 portion of the trial showed that 28% (5 of 18) of patients had objective responses (2CR, 1CRp and 2
CRi (complete remission with incomplete blood count recovery)) with median response duration of 9.1 months. Mean bone marrow
blast reduction amongst evaluable patients (14 of 18) was 67% with 57% of patients having bone marrow blast reduction of 50%
or greater and 79% (11 of 14) of patients having bone marrow blast reductions after Cycle 1 of therapy. Maximum tolerated
dose (MTD) was not reached in this trial. We have elected to progress to the Phase 2 portion of the trial at 2.0
&mu;Ci/kg/fraction, the highest dose level from the Phase 1 portion of the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 portion of the trial will enroll 53 patients and will study Actimab-A as a monotherapy. We received agreement from the
FDA for multiple revisions to the protocol for the Phase 2 portion of the clinical trial that include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removing
the use of low dose cytarabine from the Phase 2 protocol;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stipulating
Peripheral blast burden as an inclusion criteria with blasts of 200/ML being the threshold;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandating
the use of hydroxyurea in patients with peripheral blast count above 200/ML to lower their peripheral blasts below 200ML/ prior
to Actimab-A administration; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandating
the use of granulocyte colony-stimulating factor (GCSF) support.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bismab-A
trials and the Phase 1 Actimab-A trial were focused on relapsed, refractory and other difficult to treat acute myeloid leukemia
patients. The current Actimab-A multicenter Phase 1/2 trial is focused on patients newly diagnosed AML who have historically had
better outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intellectual
Property</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed or in-licensed numerous patents and patent applications and possess substantial know-how and trade secrets relating
to the development and manufacturing of our products. As of October 12, 2017, our patent portfolio includes: 68 issued and pending
patent applications, of which 10 are issued in the United States, 15 are pending in the United States, and 53 are issued internationally
and pending internationally. Additionally, several non-provisional patent applications are expected to be filed in 2018 based
on provisional patent applications filed in 2017. This is part of an ongoing strategy to continue to strengthen our intellectual
property position. About one quarter of our patents are in-licensed from third parties and the remainder are Actinium owned. These
patents cover key areas of our business, including the use of Ac-225 and other alpha emitting isotopes attached to cancer specific
carriers like monoclonal antibodies, methods for manufacturing key components of our product candidates including Ac-225, the
alpha emitting radioisotope and carrier antibodies, and methods for manufacturing finished product candidates for use in cancer
treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have licensed the rights to two issued patents in the area of drug preparation for methods of making humanized antibodies for
our product Actimab-A, which will expire in 2018 and 2019, respectively. We own three issued patents and one pending patent in
the United States and thirty-two patents outside of the United States related to the manufacturing of actinium in a cyclotron
that will expire in 2027. We own or have licensed the rights to four issued patents and one pending patent in the United States
and twenty-one patents outside of the United States related to the generation of radioimmunoconjugates that will expire in 2021,
2030 and 2032. We own or have licensed the rights to use one issued patent, one pending patent and two provisional patents for
methods of treatment with our product Actimab-A, which will expire in 2019. For Iomab-B we own one pending patent for anti-CD45
immunoglobulin composition and one pending patent the administration of a conjugated antibody.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent whose claims address methods of treating hematopoietic malignancies with Iomab-B is pending; still, we have developed a
proprietary strategy based on trade secret protection and the potential for orphan drug and data exclusivities. The BC8 antibody,
cell line and related know-how has been exclusively licensed by us from the Fred Hutchinson Cancer Research Center (FHCRC) in
exchange for milestone payments, royalties and research support.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
related to the antibody component of Actimab-A have been exclusively licensed by us from AbbVie Biotherapeutics Corp. for use
with alpha-emitting radioisotopes in exchange for future development and commercialization milestones, a royalty on net sales
for a period of 12.5 years from first commercial sale, a negotiation right to be our clinical and/or commercial antibody
supplier, a negotiation right to co-promote Actimab-A in the United States on terms to be negotiated, and the grant-back of
intellectual property (IP) rights covering improvements to the antibody for use other than with an alpha-emitting isotope.
Patents covering Ac-225 conjugated to antibodies have been exclusively licensed by us from MSKCC in exchange for license
fees, research support payments, development milestone payments, 2% royalties on net sales for the term of the licensed
patents or, if later, 10 years from first commercial sale, and 15% of any sublicense income we may receive. We source Ac-225
under an agreement with the Oak Ridge National Laboratory that expires at the end of 2017. We believe, but cannot guarantee,
that we will be able to renew this contract for additional annual periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
and Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were organized in the State of Nevada on October 6, 1997 and reorganized in the State of Delaware on March 20, 2013. Our principal
executive offices are located at 275 Madison, 7<SUP>th</SUP> Floor, New York, New York 10016. Our telephone number is (646) 677-3870.
Our website address is www.actiniumpharma.com. Information accessed through our website is not incorporated into this prospectus
and is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Securities We May Offer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the
material terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus
supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate
in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We will
also include information in the prospectus supplement, where applicable, about material U.S. federal income tax considerations
relating to the securities, and the securities exchange, if any, on which the securities will be listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell from time to time, in one or more primary offerings, our common stock, preferred stock, debt securities, warrants, rights,
purchase contracts or units, or any combination of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this prospectus, we refer to the common stock, preferred stock, debt securities, warrants, rights, purchase contracts or units,
or any combination of the foregoing securities to be sold by us in a primary offering collectively as &ldquo;securities.&rdquo;
The total dollar amount of all securities that we may issue under this prospectus will not exceed $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="pa_003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase"><B>RISK
FACTORS</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities
will contain a discussion of the risks applicable to an investment in our securities. Before deciding whether to invest in our
securities, you should carefully consider the specific factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable
prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement
or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions
discussed under Item 1A, &ldquo;Risk Factors,&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December 31,
2016, all of which are incorporated herein by reference, as updated or superseded by the risks and uncertainties described under
similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus
and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect
our operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should
not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="pa_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain &ldquo;forward-looking statements,&rdquo; which include information relating to future events, future financial performance,
strategies, expectations, competitive environment and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar
expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not
be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our
management&rsquo;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Important factors that could cause such differences include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty
regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to adequately protect our intellectual property;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
over ownership of intellectual property;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products
is an attractive alternative to other products;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intense
competition in our industry, with competitors having substantially greater financial, technological, research and development,
regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry
of new competitors and products and potential technological obsolescence of our products;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of a key customer or supplier;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technical
problems with our research and products and potential product liability claims;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
economic conditions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
federal, state and local government regulation, in the United States;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
increases for supplies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to carry out research, development and commercialization plans; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
or retirement of key executives and research scientists.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should review carefully the section entitled &ldquo;Risk Factors&rdquo; beginning on page 8 of this prospectus for a discussion
of these and other risks that relate to our business and investing in our securities. The forward-looking statements contained
or incorporated by reference in this prospectus or any prospectus supplement are expressly qualified in their entirety by this
cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or
circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="pa_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the prospectus supplement, we currently intend to use the net proceeds from the sale of securities offered
by this prospectus for general corporate purposes, including the advancement of our drug candidates in clinical trials, such as
Iomab-B, Actimab-A and Actimab-M, research and development of our alpha-particle technology platform, preclinical trials, and
to meet working capital needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
are cautioned, however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of
our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing
of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount
of competition and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this
offering for other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing
allocation of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change
in the use of proceeds include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
change in development plan or strategy;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
addition of new products or applications;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technical
delays;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
or difficulties with our clinical trials;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
results from our clinical trials;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
obtaining U.S. Food and Drug Administration approval; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
availability of other sources of cash including additional offerings, if any.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="pa_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of common stock and preferred stock summarizes the material terms and provisions of the common stock and
preferred stock that we may offer under this prospectus, but is not complete. For the complete terms of our common stock and preferred
stock, please refer to our certificate of incorporation, as amended and our bylaws, as may be amended from time to time. While
the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will
describe the specific terms of any series of preferred stock in more detail in the applicable prospectus supplement. If we so
indicate in a prospectus supplement, the terms of any preferred stock we offer under that prospectus supplement may differ from
the terms we describe below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have authorized 250,000,000 shares of
capital stock, par value $0.001 per share, of which 200,000,000 are shares of common stock and 50,000,000 are shares of preferred
stock. On October 11, 2017, there were 79,380,158 shares of common stock issued and outstanding and no shares of preferred stock
issued and outstanding. The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred
stock are available for issuance without further action by our stockholders, unless such action is required by applicable law
or the rules of any stock exchange on which our securities may be listed. Unless approval of our stockholders is so required,
our board of directors does not intend to seek stockholder approval for the issuance and sale of our common stock or preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have warrants that are outstanding, which are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative
voting. Our directors are divided into three classes. At each annual meeting of stockholders, directors elected to succeed those
directors whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders
after their election. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared
by our board of directors out of legally available funds; however, the current policy of our board of directors is to retain earnings,
if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to
share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription,
redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may
be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action
of our board of directors and issued in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the NYSE American under the symbol &ldquo;ATNM.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders,
to issue from time to time shares of preferred stock in one or more series. Each such series of preferred stock shall have such
number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall
be determined by the board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences,
conversion rights and preemptive rights. Issuance of preferred stock by our board of directors may result in such shares having
dividend and/or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights
of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issuance of shares of each series of preferred stock, the board of directors is required by the Delaware General Corporation
Law and our certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State
of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences,
rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased
(but not below the number of shares then outstanding) from time to time by action of the board of directors;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative,
and, if so, from which date;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for
adjustment of the conversion rate in such events as the board of directors may determine;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount
of such sinking fund;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
or not the shares of the series will have priority over or be on a parity with or be junior to the shares of any other series
or class in any respect;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation,
and the relative rights or priority, if any, of payment of shares of that series; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other relative rights, preferences and limitations of that series.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
designated by our board of directors, each series of preferred stock may have specific financial and other terms that will be
described in a prospectus supplement. The description of the preferred stock that is set forth in any prospectus supplement is
not complete without reference to the documents that govern the preferred stock. These include our certificate of incorporation
and any certificates of designation that our board of directors may adopt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares of preferred stock offered hereby will, when issued, be fully paid and non-assessable, including shares of preferred stock
issued upon the exercise of preferred stock warrants or subscription rights, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our board of directors has no intention at the present time of doing so, it could authorize the issuance of a series of preferred
stock that could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Common
Stock Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2013 and January 10, 2014, we issued common stock warrants to certain investors in a private placement of common
stock and warrants (the &ldquo;Common Stock Warrants&rdquo;). The Common Stock Warrants have a five year term from each closing
that occurred on December 27, 2013 and January 10, 2014, and are exercisable for an aggregate of up to 276,529 shares of our common
stock at an initial per share exercise price of $9.00, subject to adjustments as set forth below. As of October 11, 2017 we have
193,197 shares of Common Stock Warrants outstanding. We may also call this warrant for redemption upon written notice to all warrant
holders at any time the closing price of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for
20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering
the resale of the shares underlying the warrants. In the 60 business days following the date the redemption notice is deemed given
in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then
applicable exercise price per share for every share exercised. Any shares not exercised on the last day of the exercise period
will be redeemed by us at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the Common Stock Warrants are subject to adjustment upon certain events. If we at any time while the warrants
remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares
of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this warrant exist into
a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased
in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
B Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B Warrants have a five year term from December 19, 2012 and are exercisable for an aggregate of up to 1,559,505 shares
of our common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth below. As of October 11,
2017, there were 1,317,195 warrants outstanding. These warrants have a cashless exercise provision. We also have a right of first
refusal on the holder&rsquo;s sale of the warrant shares. We may also call this warrant for redemption upon written notice to
all warrant holders at any time the closing price of the common stock exceeds $1.50 (as may be adjusted pursuant to warrant agreement)
for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement
covering the resale of the shares underlying the warrants. In the 60 business days following the date the redemption notice is
deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying
the then applicable exercise price per share for every share exercised. Any shares not exercised on the last day of the exercise
period will be redeemed by us at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the Series B Warrants is subject to adjustment upon certain events. If we at any time while the warrants remain
outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of
its capital stock, or split, subdivide or combine the securities as to which purchase rights under this warrant exist into a different
number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case
of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, we shall issue any shares of common stock for no consideration or a consideration per share less than
the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment
determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)
    +</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)&nbsp;+&nbsp;N(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by us for the total number of such additional
shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable, in effect
immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Offering Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to 2,682,155 shares
of our common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth below (anti-dilution).
As of October 11, 2017, there were 1,239,997 warrants outstanding. These warrants have a cashless exercise provision. We also
have a right of first refusal on the holder&rsquo;s sale of the warrant shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
warrants have a cashless exercise provision. We also have a right of first refusal on the holder&rsquo;s sale of the warrant
shares. The exercise prices of the Stock Offering Warrants are subject to adjustment upon certain events. If we at any time
while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common
Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under
this warrant exist into a different number of securities of the same class, the exercise price for such securities shall be
proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a
combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Consulting
Firm Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consulting Firm Warrants have a term ending on December 17, 2019 and are exercisable for an aggregate of up to 3,755,560 shares
of the Company&rsquo;s common stock. As of October 11, 2017, there were 1,502,223 warrants outstanding. These warrants may not
be exercised by the Holder upon less than 90 days prior written notice of such exercise and provided further that that the Holder
may elect, in its sole discretion, to waive the Prior Notice Requirement, in whole or in part, upon 65 days prior written notice
of such waiver. These warrants have a cashless exercise provision and were issued at an initial per share exercise price of $0.001,
subject to adjustment as if the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend
or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine
the securities as to which purchase rights under this warrant exist into a different number of securities of the same class, the
exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately
increased in the case of a combination. The warrants are also subject to piggy-back registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2015
Offering Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Offering Warrants have a term ending February 11, 2019 and are exercisable for an aggregate of up to 3,333,333 shares of
our common stock at $6.50 per share. As of October 11, 2017, there were 3,333,333 warrants outstanding. The exercise price and
the number of warrant shares shall be adjusted from time to time if we at any time on or after the issuance date subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of common stock
into a greater number of shares, the exercise price in effect immediately prior to such subdivision will be proportionately reduced
and the number of warrant shares will be proportionately increased. If we at any time on or after the issuance date combines (by
combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number
of shares, the exercise price in effect immediately prior to such combination will be proportionately increased and the number
of warrant shares will be proportionately decreased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at any time prior to the expiration date we grant, issue or sell any Options, Convertible Securities or rights to purchase stock,
warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;Purchase
Rights&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this warrant (without regard to any limitations on the exercise of this warrant) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the holder exceeding the Maximum Percentage, then the holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Maximum Percentage (as defined in the warrant), at which time the Holder shall be granted such right
to the same extent as if there had been no such limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Placement
Agent Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued three types of warrants to the Placement Agent, Placement Agent Stock Offering Warrants, Placement Agent Common Stock
Warrants, and Placement Agent December 2013 Offering Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Placement
Agent Stock Offering Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to
1,251,022 shares of our common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth
below (anti dilution). As of October 11, 2017, there were 355,293 warrants outstanding. These warrants have a cashless
exercise provision. The exercise prices of the warrants are subject to adjustment upon certain events. If we at any time
while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common
Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under
this warrant exist into a different number of securities of the same class, the exercise price for such securities shall be
proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a
combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Placement
Agent Common Stock Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent Common Stock Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to
467,845 shares of our common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth below.
As of October 11, 2017, there were 298,065 warrants outstanding. These warrants have a cashless exercise provision. We may also
call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock
exceeds $1.50 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided
at such time there is an effective registration statement covering the resale of the shares underlying the warrants. In the 60
business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose
to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.
Any shares not exercised on the last day of the exercise period will be redeemed by us at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants are subject to adjustment upon certain events. If we at any time while the warrants remain outstanding
and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital
stock, or split, subdivide or combine the securities as to which purchase rights under this warrant exist into a different number
of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend,
split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, we shall issue any shares of common stock for no consideration or a consideration per share less than
the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment
determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)
    +</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)&nbsp;+&nbsp;N(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of
such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable,
in effect immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Placement
Agent December 2013 Offering Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent December 2013 Offering Warrants have a five year term from January 10, 2014 and are exercisable for an
aggregate of up to 138,265 shares of our common stock at an initial per share exercise price of $9.00, subject to adjustment
as set forth below. As of October 11, 2017, there were 124,997 warrants outstanding. These warrants have a cashless exercise
provision. We may also call this warrant for redemption upon written notice to all warrant holders at any time the closing
price of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days,
as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the
shares underlying the warrants. In the 60 business days following the date the redemption notice is deemed given in
accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then
applicable exercise price per share for every share exercised. Any shares not exercised on the last day of the exercise
period will be redeemed by us at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants are subject to adjustment upon certain events. If we at any time while the warrants remain outstanding
and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital
stock, or split, subdivide or combine the securities as to which purchase rights under this warrant exist into a different number
of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend,
split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Consultant
Warrants.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 11, 2017, we had outstanding warrants exercisable for 507,833 shares of common stock issued to various consultants
in consideration for services. The exercise prices range from $0.98 to $11.66 per share. These warrants do not have a cashless
exercise provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2017
Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017 in connection with an offering, we issued warrants to purchase 18,275,000 shares of Common Stock (the &ldquo;Warrants&rdquo;).
The Warrants are exercisable commencing on the issuance date at an exercise price equal to $1.05 per whole share of common stock,
subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the date
of issuance. These warrants do have a cashless exercise provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2015, we entered into an Investor Rights Agreement (the &ldquo;Investor Rights Agreement&rdquo;) with Memorial Sloan
Cancer Center (&ldquo;MSKCC&rdquo;). Under the terms of the Investor Rights Agreement, Actinium has granted MSKCC piggyback registration
rights that would be triggered in the event Actinium were to engage in a public registered offering of its shares for its own
account where other shareholders are participating as selling shareholders or where such public registered offering is for the
account of other selling shareholders. In addition, Actinium has granted MSKCC unlimited Form S-3 registration rights with respect
to its shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Anti-Takeover Law, Provisions of our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Anti-Takeover Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years
after the date of the transaction in which the person became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also
officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or
special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines a business combination to include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
merger or consolidation involving the corporation and the interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to
the interested stockholder; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person.
The term &ldquo;owner&rdquo; is broadly defined to include any person that, individually, with or through that person&rsquo;s
affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not
the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise
or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial
owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject
to Section 203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock
that is listed on a national securities exchange or authorized for quotation on the Nasdaq Stock Market or held of record by more
than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price
above the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certificate
of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in
our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their
shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions
could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
our board of directors to issue up to 50,000,000 shares of preferred stock, without further action by the stockholders, with any
rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative
vote of a majority of directors then in office;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide
our board of directors into three classes, with each class serving staggered three-year terms, with such three year term commencing
on the election of a director on and after the 2014 annual meeting;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled
to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that special meetings of our stockholders may be called only by our Chairman of the Board, board of directors, chief executive
officer, or the holders of not less than one-tenth of all the shares entitled to vote at the meeting; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
forth an advance notice procedure with regard to business to be brought before a meeting of stockholders.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="pa_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under
this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable
prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described
below. Unless the context requires otherwise, whenever we refer to the indenture, we are also referring to any supplemental indentures
that specify the terms of a particular series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture
will be qualified under the Trust Indenture Act of 1939, as amended (&ldquo;Trust Indenture Act&rdquo;). We have filed the form
of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms
of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement
of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety
by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read
the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer
under this prospectus, as well as the complete indenture that contains the terms of the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Terms of the Indenture</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to
the principal amount that we may authorize and may be in any currency or currency unit designated by us. Except for the limitations
on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture
do not contain any covenants or other provisions designed to afford holders of any debt securities protection with respect to
our operations, financial condition or transactions involving us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities issued under the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at
a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at
a discount, may, for U.S. federal income tax purposes, be treated as if they were issued with &ldquo;original issue discount,&rdquo;
or &ldquo;OID,&rdquo; because of interest payment and other characteristics. Special U.S. federal income tax considerations applicable
to debt securities issued with original issue discount will be described in more detail in any applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
title of the series of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
limit upon the aggregate principal amount that may be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
maturity date or dates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
form of the debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
applicability of any guarantees;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms
of any subordination;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is
a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration
of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into
another security or the method by which any such portion shall be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin
to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining
such dates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at
our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of
those redemption provisions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or
analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities
and the currency or currency unit in which the debt securities are payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
denominations in which we will issue the series of debt securities, if other than denominations of $1,000, and any integral multiple
thereof;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for
our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing
of debt securities of that series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms
and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual
securities; and the depositary for such global security or securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions
upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable,
or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&rsquo; option) conversion
or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall
be payable upon declaration of acceleration of the maturity thereof;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation,
merger or sale covenant;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders
to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of
debt securities issued under the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S.
dollars;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions
upon which the election may be made;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal
amounts of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
restrictions on transfer, sale or assignment of the debt securities of the series; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes
in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
or Exchange Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable
for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether
conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which
the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would
be subject to adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidation,
Merger or Sale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not
contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our
assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary
of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
of Default Under the Indenture</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events
of default under the indenture with respect to any series of debt securities that we may issue:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we fail to pay any installment of interest on any debt securities of that series, as and when the same shall become due and payable,
and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by
us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest
for this purpose;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we fail to pay the principal of (or premium, if any) on any debt securities of that series as and when the same shall become due
and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous
fund established with respect to that series; provided, however, that a valid extension of the maturity of such debt securities
in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal
or premium, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we fail to observe or perform any other covenant or agreement with respect to that series contained in the indenture or otherwise
established with respect to that series pursuant to the indenture, other than a covenant or agreement specifically included solely
for the benefit of one or more debt securities other than that series, and our failure continues for 90 days after we receive
written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from
the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series;
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default described
in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt
securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of (premium, if any) and accrued and unpaid interest, if any, due and payable immediately. If an event of default
specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of that
series shall be automatically due and payable without any declaration or other action on the part of the trustee or any holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event
of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal,
premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver
shall cure the default or event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under
no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of
the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a
majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and
place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the
trustee, with respect to the debt securities of that series, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability
or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a
receiver or trustee, or to seek other remedies only if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
holder has given written notice to the trustee of a continuing event of default with respect to that series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by
the trustee in compliance with the request; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of
the outstanding debt securities of that series other inconsistent directions within 90 days after the notice, request and offer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
of Indenture; Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the trustee may change an indenture without the consent of any holders with respect to specific matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
comply with the provisions described above under &ldquo;Description of Debt Securities&mdash;Consolidation, Merger or Sale;&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
provide for uncertificated debt securities in addition to or in place of certificated debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the
benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance,
of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any
right or power conferred upon us in the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue,
authentication and delivery of debt securities, as set forth in the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above
under &ldquo;Description of Debt Securities&mdash;General&rdquo; to establish the form of any certifications required to be furnished
pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series
of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with
the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of
each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series
of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding
debt securities affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending
the fixed maturity of any debt securities of any series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon
the redemption of any series of any debt securities; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or
waiver.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discharge</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities,
except for specified obligations, including obligations to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
for payment;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register
the transfer or exchange of debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">replace
stolen, lost or mutilated debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
principal of and premium and interest on any debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
paying agencies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hold
monies for payment in trust;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recover
excess money held by the trustee;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensate
and indemnify the trustee; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoint
any successor trustee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to
pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form,
Exchange and Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in
the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that
we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited
with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in a prospectus
supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry,
a description of terms relating will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described
in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for
other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or
with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the
security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the
debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar,
that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation
of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required
to maintain a transfer agent in each place of payment for the debt securities of each series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we elect to redeem the debt securities of any series, we will not be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue,
register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business
15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending
at the close of business on the day of the mailing; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register
the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion
of any debt securities we are redeeming in part.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Concerning the Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only
those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee
must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to
this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any
holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that
it might incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
and Paying Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on
any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered
at the close of business on the regular record date for the interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments
by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with
respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for
the debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities
that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable (or such shorter
period set forth in applicable escheat, abandoned or unclaimed property law) will be repaid to us, and the holder of the debt
security thereafter may look only to us for payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except
to the extent that the Trust Indenture Act is applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 11, 2017, there were 27,147,183 shares of common stock that may be issued upon exercise of outstanding warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants for the purchase of debt securities, common stock or preferred stock in one or more series. We may issue warrants
independently or together with debt securities, common stock or preferred stock, and the warrants may be attached to or separate
from these securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will evidence each series of warrants by warrant certificates that we may issue under a separate agreement. We may enter into
a warrant agreement with a warrant agent. Each warrant agent may be a bank that we select which has its principal office in the
United States. We may also choose to act as our own warrant agent. We will indicate the name and address of any such warrant agent
in the applicable prospectus supplement relating to a particular series of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe in the applicable prospectus supplement the terms of the series of warrants, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
offering price and aggregate number of warrants offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with
each such security or each principal amount of such security;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the date on and after which the warrants and the related securities will be separately transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the case of warrants to debt securities, purchase common stock or preferred stock, the number or amount of shares of common stock
or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which and currency in which
these shares may be purchased upon such exercise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
manner of exercise of the warrants, including any cashless exercise rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
warrant agreement under which the warrants will be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">anti-dilution
provisions of the warrants, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
terms of any rights to redeem or call the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable
during that period, the specific date or dates on which the warrants will be exercisable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
manner in which the warrant agreement and warrants may be modified;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
identities of the warrant agent and any calculation or other agent for the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
income tax consequences of holding or exercising the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
terms of the securities issuable upon exercise of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may
be listed or quoted; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including, in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any,
or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise
price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement,
holders of the warrants may exercise the warrants at any time up to 5:00 P.M. eastern time, the close of business, on the expiration
date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together
with specified information, and paying the required exercise price by the methods provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate, and in the applicable prospectus supplement, the information
that the holder of the warrant will be required to deliver to the warrant agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office
of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities
purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we
will issue a new warrant certificate for the remaining amount of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforceability
of Rights By Holders of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship
of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement
or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.
Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate
legal action the holder&rsquo;s right to exercise, and receive the securities purchasable upon exercise of, its warrants in accordance
with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Agreement Will Not Be Qualified Under Trust Indenture Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
warrant agreement will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee, under the
Trust Indenture Act. Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust
Indenture Act with respect to their warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant agreement and any warrants issued under the warrant agreements will be governed by New York law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to our stockholders to purchase shares of our common stock or preferred stock. We may offer rights separately
or together with one or more additional rights, debt securities, preferred stock, common stock or warrants, or any combination
of those securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be
issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. The rights
agent will act solely as our agent in connection with the certificates relating to the rights of the series of certificates and
will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial
owners of rights. The following description sets forth certain general terms and provisions of the rights to which any prospectus
supplement may relate. The particular terms of the rights to which any prospectus supplement may relate and the extent, if any,
to which the general provisions may apply to the rights so offered will be described in the applicable prospectus supplement.
To the extent that any particular terms of the rights, rights agreement or rights certificates described in a prospectus supplement
differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus
supplement. We encourage you to read the applicable rights agreement and rights certificate for additional information before
you decide whether to purchase any of our rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide in a prospectus supplement the following terms of the rights being issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
date on which stockholders entitled to the rights distribution will be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
aggregate number of shares of common stock or preferred stock purchasable upon exercise of the rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
exercise price;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
aggregate number of rights issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
date, if any, on and after which the rights will be separately transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
date on which the ability to exercise the rights will commence, and the date on which such ability will expire;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
conditions to the completion of the offering, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
withdrawal, termination and cancellation rights, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
applicable material U.S. federal income tax considerations; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of
the rights.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
right will entitle the holder of rights to purchase, for cash, the number of shares of common stock or preferred stock at the
exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business
on the expiration date for the rights provided in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly
completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus
supplement, we will, as soon as practicable, forward the shares of common stock or preferred stock, as applicable, purchasable
upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed
securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination
of such methods, including pursuant to standby arrangements, as described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="pa_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF PURCHASE CONTRACTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific
or variable number of our debt securities, shares of common stock, preferred stock, warrants or rights, or securities of an entity
unaffiliated with us, or any combination of the above, at a future date or dates. Alternatively, the purchase contracts may obligate
us to purchase from holders, and obligate holders to sell to us, a specific or variable number of our debt securities, shares
of common stock, preferred stock, warrants, rights or other property, or any combination of the above. The price of the securities
or other property subject to the purchase contracts may be fixed at the time the purchase contracts are issued or may be determined
by reference to a specific formula described in the purchase contracts. We may issue purchase contracts separately or as a part
of units each consisting of a purchase contract and one or more of our other securities described in this prospectus or securities
of third parties, including U.S. Treasury securities, securing the holder&rsquo;s obligations under the purchase contract. The
purchase contracts may require us to make periodic payments to holders or vice versa and the payments may be unsecured or pre-funded
on some basis. The purchase contracts may require holders to secure the holder&rsquo;s obligations in a manner specified in the
applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being
delivered, including, to the extent applicable, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase
under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the purchase contracts are to be prepaid;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the securities
subject to purchase under the purchase contract;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
applicable federal income tax considerations; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the purchase contracts will be issued in fully registered or global form.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding description sets forth certain general terms and provisions of the purchase contracts to which any prospectus supplement
may relate. The particular terms of the purchase contracts to which any prospectus supplement may relate and the extent, if any,
to which the general provisions may apply to the purchase contracts so offered will be described in the applicable prospectus
supplement. To the extent that any particular terms of the purchase contracts described in a prospectus supplement differ from
any of the terms described above, then the terms described above will be deemed to have been superseded by that prospectus supplement.
We encourage you to read the applicable purchase contract for additional information before you decide whether to purchase any
of our purchase contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in
any combination. Each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of
a holder, of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities
included in the unit may not be held or transferred separately, at any time or at any times before a specified date or upon the
occurrence of a specified event or occurrence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement will describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
designation and the terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
unit agreement under which the units will be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
the units will be issued in fully registered or global form.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="pa_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities being offered pursuant to this prospectus to or through underwriters, through dealers, through agents,
or directly to one or more purchasers or through a combination of these methods. The applicable prospectus supplement will describe
the terms of the offering of the securities, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
name or names of any underwriters, if any, and if required, any dealers or agents;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
purchase price of the securities and the proceeds we will receive from the sale;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
underwriting discounts and other items constituting underwriters&rsquo; compensation;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
discounts or concessions allowed or re-allowed or paid to dealers; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
securities exchange or market on which the securities may be listed or traded.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may distribute the securities from time to time in one or more transactions at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
fixed price or prices, which may be changed;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
prices prevailing at the time of sale, directly by us or through a designated agent;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prices
related to such prevailing market prices; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiated
prices.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name
of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation
of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting
syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated.
If an underwriting syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement.
If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may
be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or
at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or reallowed
or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations
of the underwriters to purchase the offered securities will be subject to conditions precedent, and the underwriters will be obligated
to purchase all of the offered securities, if any are purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may grant to the underwriters options to
purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions
or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth
in the prospectus supplement for those securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will
sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to
be determined by the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified
in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities directly or through agents we designate from time to time. We will name any agent involved in the offering
and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus
supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the
public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts </FONT>providing for
payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers
of the securities for whom they act as agents, in the form of discounts, concessions or commissions. Underwriters may sell the
securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that
participate in the distribution of the securities, and any institutional investors or others that purchase securities directly
for the purpose of resale or distribution, may be deemed to be underwriters, and any discounts or commissions received by them
from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under
the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may provide agents, underwriters and other purchasers with indemnification against particular civil liabilities, including liabilities
under the Securities Act of 1933, as amended, or contribution with respect to payments that the agents, underwriters or other
purchasers may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services
for, us in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To facilitate the public offering of a series
of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the
market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons
participating in the offering of more securities than have been sold to them by us. In addition, those persons may stabilize or
maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby
selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by
them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain
the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if
commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect
that the transactions described above, if implemented, may have on the price of our securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified in the applicable prospectus supplement, any common stock sold pursuant to a prospectus supplement will be
eligible for listing on a national securities exchange, such as the NYSE American or NASDAQ, subject to official notice of issuance.
Any underwriters to whom securities are sold by us for public offering and sale may make a market in the securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of some states, if applicable, the securities offered pursuant to this prospectus will
be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or
qualification requirement is available and complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon by The Matt Law Firm, PLLC Utica, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the fiscal year ended
December 31, 2016 have been so incorporated in reliance on the report of GBH CPAs, PC, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith
file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission.
Such reports, proxy statements and other information can be read and copied at the Securities and Exchange Commission&rsquo;s
public reference facilities at 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates. Please call the Securities and
Exchange Commission at 1-800-732-0330 for further information on the operation of the public reference facilities. In addition,
the Securities and Exchange Commission maintains a website that contains reports, proxy and information statements and other information
regarding registrants that file electronically with the Securities and Exchange Commission. The address of the Securities and
Exchange Commission&rsquo;s website is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through our website at www.actiniumpharmaceuticals.com, our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such
material with or otherwise furnish it to the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended,
relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional
relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration
statement. You can obtain a copy of the registration statement, at prescribed rates, from the Securities and Exchange Commission
at the address listed above, or for free at www.sec.gov. The registration statement and the documents referred to below under
&ldquo;Incorporation of Certain Information By Reference&rdquo; are also available on our website, www.actiniumpharmaceuticals.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a
part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="pa_016"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities and Exchange Commission allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it,
which means that we can disclose important information to you by referring you to those documents. The information we incorporate
by reference is an important part of this prospectus, and later information that we file with the Securities and Exchange Commission
will automatically update and supersede this information. We incorporate by reference the documents listed below and any future
documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the Securities and Exchange
Commission pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Securities Exchange Act of 1934, as amended, subsequent to the
date of this prospectus and prior to the termination of the offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016_actiniumpharma.htm">March 16, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017, filed with the Securities and Exchange Commission on
<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317_actiniumpharma.htm">May 15, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017, filed with the Securities and Exchange Commission on
<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617_actiniumpharma.htm">August 4, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717_actiniumpharma.htm">March 28, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017004962/f8k050517_actiniumpharma.htm">May 11, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005355/f8k051217_actiniumpharma.htm">May 16, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005912/f8k051217a1_actiniumpharm.htm">May 26, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017006261/f8k060517b_actiniumpharma.htm">June 8, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017006302/f8k060517a_actiniumpharma.htm">June 9, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017006575/f8k061517_actiniumpharma.htm">June 16, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007104/f8k070317_actiniumpharm.htm">July 3, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Report on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007992/f8k072817_actiniumpharma.htm">July 28, 2017</A>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of our common stock, which is contained in our Form 8-K/A, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013000373/f8k122812a2_cactusventures.htm">January 28, 2013</A>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
filings filed by us pursuant to the Securities Exchange Act of 1934, as amended, after the date of the initial filing of this
registration statement and prior to the effectiveness of such registration statement (excluding information furnished pursuant
to Items 2.02 and 7.01 of Form 8-K) shall also be deemed to be incorporated by reference into the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else
to provide you with different information. You should not assume that the information in this prospectus is accurate as of any
date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a
copy of any or all of the information that has been incorporated by reference in this prospectus but not delivered with this
prospectus (other than an exhibit to these filings, unless we have specifically </FONT>incorporated that exhibit by reference
in this prospectus). Any such request should be addressed to us at: 275 Madison Avenue, 7th Floor, New York, New York 10016,
Attention: Steve O&rsquo;Loughlin, Principal Financial Officer, or made by phone at (646) 677-3875. You may also access the
documents incorporated by reference in this prospectus through our website at www.actiniumpharmceuticals.com. Except for the
specific incorporated documents listed above, no information available on or through our website shall be deemed to be
incorporated in this prospectus or the registration statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt">100,833,334<FONT STYLE="font-family: Times New Roman, Times, Serif">
Shares of Common Stock</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt/19.2pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center">Pre-Funded Warrants to
Purchase up to 82,500,001 Shares</P>

<P STYLE="font: 14pt/19.2pt inherit,serif; margin-top: 0; margin-bottom: 0; text-align: center">of Common Stock</P>

<P STYLE="font: 14pt/19.2pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B><I>Sole
Book-Running Manager</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">H.C.
Wainwright &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Co-Managers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; width: 33%; vertical-align: bottom"><FONT STYLE="font-size: 12pt"><B>Maxim Group LLC</B></FONT></TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 33%; vertical-align: bottom"><FONT STYLE="font-size: 12pt"><B>JonesTrading</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
21, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQG_/2OR3%4O9RDNS:?\ 7]=>Y]MA:OM(I]XIK3R+5%>>>&OBS\-?&/B_Q?X
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M6=5U35--BF<Z1;'3K"X(OHKN*+]/O"ND7@")'+.BMP56614 ;&X8!"X;)W
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M37=:_M&5=5L])@U>[BMS:V%M)?RM:7-^T;0M#<>\^ OA5^V!H?@OQKIOB_\
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MZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#9'I]OX]^&E@-MU\0?!-K@#<+CQ1HL)&!GGS+P8QGG/J1R<X^'K+Q!X7RO\
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M^R'%GS/VIOV<XL=?,^-OPT0#ZA_$P&/\*R[C]M+]C)1B7]K;]F6+K_K/CO\
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MI73Q;3PG$.,6)P>'=##4<-A\)AX3LZLJ5!5+5*K7,N><JDGR\TN2*C%R;3/
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MTO8R_"5<XQ<,14PT*,*<5&%E>4KRNY2?*O=6D8IKTTN;7AGPZ(Q&3'R0.._
M'./PX!/?G../9--TY84!"@].QW#CL.AS^6.1GH*^E:<D*(2O. .@[ 8' '/4
M8YR.<=ZZR" (!@#VR#C'4EAW)Z=><$<8.?YVS''SKSDW*ZOWW^]]-E_5_P!3
MR_ 0P\(Q4;65KVVVV:2U_P"&M9#X8@HZ8;;U]!R0<>O/'IC/89_)?X$_#_P/
M^V;^TA^TK\>OB7X5T7Q]\,?"^K6'P1^$NE^([!-4T.6W\)DW&NZ_9VUUOA\Z
M:XDANX)@IVKXANPNT@&OO3XV?!'6/C-'IFFP_&CXJ?##P[!8ZI8:_HOPTO\
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M[WW&<\_AU%?UGW'_  52_8!M<_:/VC?#\6#@Y\)_$8C/U7P:16-/_P %<O\
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M/$MY-XO\-'2-',-EK'@G0K&2"RNSNN9I-1CECM6Q'%-Y:JO]-.M:PD0D^<
M<@D=L]^#D<?GGH*^8XOK8'-<YPL\KJTL1AJ65X/#<U%RE"-2G4Q3G%RE"FY3
M_>1G)N+;=2[D];<E*I4P]"JZ[?/.O4J-RTDU)02LDVE\/*E=)**2L5M;UE(D
M;YA@!LD'(/?KT![X!QT]<#Y_\6>(@WF ."1GOTZY&?TQSZ<=*F\>>.--T/3-
M7UK6-1M]+T?1=.U#6-6U.[DV6NFZ5I5I+?ZC?W3CD06=G;S7,I7<?+B?:&)
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M/FVG/&#H?\$RK^'3OV*O!^HWDC+::;JWQ&O+A^7,5K:>*M9N9BJYZ*B2,$!
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MMXRT=HI(?$5OJ]I9V%MH7B\VT$?B_2/$.F/=ZE;YN-3FM(;:*X^V0"::W?\
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M((Z#C)R/P!'%7UN%/.=N><$Y'X=,=S@$]O45XGIGBF.2-29%' !R>O'3IG(
MQR<9[=">OMO$$;A07!X'0@\'OCMD8XY)YXXS7Y[B,LJTV[PDK-ZI6_!JW]=S
M[G#YE2J)-3C\W?Y73?\ 6YZ&) >F/SQSU[@=!U]^/>E+@#/'3GYAP?3N>O4@
M?GTKDTUF%L'?U &1@DC\NA[<C//.:>=6B .7 ZCO@^O!/(QWX]B<UPO"5+[/
MYQ?]?U]W:L5!K=?>O^&.E:91U)[\#KQUYZ^O0#CG/3.=<7:H#\P4 8QD#GW/
M3\.A&2>17-W.N1*"-W.#SP,?3Z<8 Q@]1BN0U3Q+'&K?O.>NT8V@CL3GW^HZ
M\\5UX?+JM222BW>VZ_&UK_H<N(Q]*G%MSBK)Z)J_S=[+;U['0ZMK2QJR[^@!
MR<'U/IC/?CJ>.>_B'B;Q/M\P+)V.?FZ\]3ZD]SUZ <<U@>-?B%I&AZ9J6MZ[
MK6F:'HFEV[WFJZQK6H6FE:3IMM&,/<:AJ5_/!96<"\!IKB=$R0@8E@I^2O#_
M .TA\&/BWJ%]I7PQ^,'PV^(&IV*22WFG>#O&N@>(-1@AC)$DS6&G7TUTT,8!
M,D\43PHN&D= 17Z!D?#E:<?;O#U)4Z;7M*BI5)0@VKKVE14G"#>GQSCI:R/@
M<]XAC"$X4Y:V>B?]:7]/DG8N_M Z+??%/X2_%CX:Z??0V-]\0?AMXZ\%6-[<
MDFVM;_Q/X:U+1K*>X(.1;QW5[$T[C.R+>^#MK^%_PG\9_CA^R7XA\0_#/6+#
M4/!_BSPK>7.A:[H&KB;3-3TR[MF,$J+O5/M-A<;?-L;Z#?:7]G)%<VLLT$J.
M?[LTCDNI,\G<?E'7J<'CCC/7'>GZK^SW\(OBE>6%]\2_A)\-/B'?V,:P65]X
MV\#>&?%-]9PJ1MM[:]UK3+RY2!3G9 LGEKSL09-?KN1\0X'AG"XK"XW QQ^"
MQ3I59T8SITZD*]&$J<91=2,H2@X2<)1ERM-*49-\T7\#A:N/Q>+=6A*4)RO%
M35W:+>S3333WM;2R?D?S^_\ !#KP!\8_C1^T'\2/VK?%FFWMG\-='^'VK_#C
M0M;N;>>"P\6^+_$VM:)J%_::#/,JKJUMX<TW17GUJ_MO,M+6^OM.L?-^U-,D
M?]6MTGAOP7X8USQ?XQUK2/"_A/PMH]]K_B7Q)KU];Z9HFA:)I=N]UJ&JZMJ5
MV\=O9V5G;QO)-/*ZX VH"[*C4;*U\"?"GP/?:]K][X4^&_PY\ Z!=ZIJNIWK
M:9X5\&>#_#&CP/=7UY<,JV6DZ-I-C;H\LGEK%#D[4C>60*W\6?\ P4\_X*B_
M$O\ X*+^,W^!G[.^A^.M#_8Y\,>((+>.2W\.Z[::O\>]?TVY!M?&?C6WCM!+
MI_@:PE07W@KP+>E99(TB\3>)8&U5M/T_1?@\ZS+%\;YY6KX6C#+<NP].A1G-
M/FHX+"4(RC2@ZC]G#$8VLG5E"G'E4I3<Y*GAJ/-5_2,HRA8:FJN)<J^(JR<F
MW'WZDY6OI:7+3@K)MZ1225ZDK1_LJ^#OQ3^#W[2_POT3XP? WQGI?Q ^'GB,
MWEOIVNZ;'<6TD%]IT[6^H:7J^E:A#:ZKH6KV;A9+C2M6L[2]6WEMKL0FVN;>
M:3\*O^"QW_!,CXI?M)Z[X1_:%_9YM[?6?BCX/\,KX,\7> 9]2MM&O_%OAG3K
M^]U70=8\):E?S6^F_P#"1Z'-J6HV-UHU]=V2:MIUU;/9W/VVR-O=_GW_ ,$_
MOVD?B7^R#\0G\3>"D;6_ _B62TL?BC\+9;A[/0O&VG6.+6#4M,$N^+0?'.A0
MEQX;U\1@O"O]A:VMSI<VVU_K\\%^./ GQQ\ :-\2/ASJJZSX9U^ M&TL1M]3
MTJ_B %]H6OZ<Y,VE:[I4Q^S:AI\Q)5E6>!Y[2:WN)?.RS.,PX.SREC,%556D
MG4C2E7BJD*M&K'EJX7%PBXIN4$O?IN"FXPJTG"I&5,[,ZR&GB<,[0:=DU*.C
MC..J::6C3VZ/5.Z::_A,^$O_  2__;P^-'B[3/"7Q1\"^-?@Y\/H[V&/Q7XN
M^)4]EIZ6.BI(OV\>'-$AOKG4O$FM2VXDBTR"" :<MRT4U_?V]JCLW]AGP\LM
M+\!^&_"_@SP]%):>'O"/A[0_"NA6TC^9+!I'A[3;72=-BED/^LE6SM(!+)_'
M*7? ! 'L'BCPV5\S"?WL<#CG[P/..@S[=C7D-W;O92.798UC5Y9&D9(XXXHU
M+O+)(Y6..-$5WDD=E2-%9V95!-?H69<3U>+*5%8BGAL/1HJ<J6&PL91IQJ5%
M%5*LG4<ISJ245&\K*,%RQC[TI/\ *L91Q> Q*DY5)<CLI2<G)I/N[M=DDTD^
MS/IWPIXEX12^22 26SGG'0XXSTY!!Q[FO>]$U<2HF#NR!CG)7.3R/?H,=<D_
M7\)?^'HW[%WA7Q/=^&;GXQ/JTNF7K6&HZ]X4\&>,_%?A"QNHI/*N$;Q3H>B7
MNE7L5M(KK<76ER:A:Q;'_?LJ,:_5[X4_$;PSX^\-Z#XQ\%^(]'\5^$O$EC#J
M6@^(] OH=1TG5K&7*I<V5Y [1N ZO'-"P2XMITEMKJ*&XBDB7\SXGX:Q>#@L
M16P>(P]*JW[.=7#U:4)OEY[1E.$5S<MI<KY9<KOR-*Z^_P"'<YG-0A4YDVE9
M24ES+2]KI73[JZOZV?US:SAP.<[@O?OSR/<\ 8SCOP>?Y;_^"EV?^&U?B5V/
MV#X:<#T_X0[0L'_@0_SS7](/B73?$GBKP7KV@>$?&=S\/O$FJV'V32?&MCI&
MGZ]>>';AYHG>^M-'U0C3[Z?R$FMXTNCLB,WGC+QJ#^<NN_\ !)?PYXZUK4?%
M?C_]H[XK^,/%^LS)<ZOXCU'2_#8O;^>.*.&)Y/.CO'1((HHXK6&.=8K6WCBM
M[=(XXE ^E\#^)N%> N(LSXBXFSOZC&KE>)R;#Y;A\JS7,,96EB:^!Q3QKJ86
MFL%1PM-8:5'DG6EBJE65U2A2ASS_ "+Z4' _'?BGPEDG!_!/#2S.='/L#Q)B
M\XQ>?9%E&78>&!P^9X-99&CCJLLQQ&-K?788A5:>&A@:5"/+/$5,1+V4/UKT
M8?\ $HTK(Z:;8]?7[+%6E7S=\"_@O\3_ (47^L'QI^T;XW^-6@W>EV5AHFB>
M,O#GAK3Y_#]Q:SL\E_'K>CQQZAJ4ES;E+5X;W,:+&)5)E+$_2-?B&;8;"83'
MUZ.!S3#9QADXU*>/PN&Q^#HU?:J524%A\SH4,93G1<O9U%.FX.:;I5*D+3?]
M,9#C<PS#*L-B<SR/&<.XUJ=*KE6/QN4YAB*'L'&C&J\7DF)Q>75:6)C!UJ+I
M5545-I5Z5&K>FOY^O^"TG_(Y?!'_ +$CX@?^G/0*_<[X9_\ )-_A]_V)'A3_
M -,-A7Y__M#_ /!/#Q'^TSXN7Q+\2/VE/$-S9:4=9M/".@V7PU\*65OX:T+5
M[Y;MM*^U6>HVLNK3(D-I!-J=[&+JY^R1R$0[G0_4/A;X.?&'PS\(M5^'(_:/
MUG4/$VS2+#PA\29?AMX*BU3P?H6E0:9:?V9'H*B31]=GN+6RNHVU75Q)>1R7
M[3C?);0Y_7^+,ZX7S;PU\-.%L%Q/@9YKPQB,R6;1GEW$%/#TZ>=XCG]M1KRR
MRV(AET:C>-C""JS]G-8&.*;@I_SSP#PWQQD'C1XU\<YEP3FE/(>-\)DLN'YT
M\XX3K8NM5X8P?LI8?$X:&=\V$J9Q4I)97.I.5"'MJ;S2I@$JKI_B9_P3B_Y/
MY\8_]@KXW?\ J6Z=7Z8?MG_MH?#S]DS6;6'0_ .D>,_CGXL\/Q7*.;>UTP:9
MX7M[FYM=.NO%7B*WM)-9N[22]BNXM'\/6KM+.8;R9I].A"33^>?#+_@F=XB^
M#OQ$/Q4^'W[4/B;2O&TQU=;[4K[X8>$]6M]1M]?NX[W6[:[T^ZU06NS4;F))
M7>%(7@=5-LT. *]/_:W_ .">W@_]JCQ9HOCR3QYK/@/Q=I^@P>&M5N;/1K/7
M=*UW2[.XN;FR:;3;B]T^:QO[22^NT2ZMK]HY;>2.&:U9X8YQ]AQ/Q1X5<4^*
M60YYGF=XG'<'0X5PF4YE1P>"S_!U'F.4X51P]#,Z,:.%Q5;*,;7FY-8*I6G4
M^KTH8JEAX-U%^=\$<#^._ W@9Q9PSPQPS@LJ\1:O'N9<09-B,QS/A3,*$<HX
MAQ[J8K%9-B)XG&X##\0Y;A(*G%YE1P]*D\56J8&MBZD52?Q?^VGX'^/^K_LE
M3_&']HSXK3/XBU'Q!X!N=!^"G@FPL= ^&WA-=>U:!1;ZP72[USQCXGT_3[J=
MQ=WVJM::5<Q3BS2[2(73?8__  2WN((_V/O -L\\*7%QXE^)<EO TL:S3QV_
MC75!.\41822)"9HA,R*RQ^;'O*^8F[JK/]AO2?$O@*;P1\>_B_\ $;X\)!X9
MF\,>&)_$!TKP_IO@B-[>*VM_$'AO1='M72X\96,4,45KXJ\3WGB+5(;<3VL,
MD-K?ZC#=\U^SI_P3\TS]G2\\1>(-%^,'BSQ+XNE\.:YX:^'NKZYHNFMI'PT@
M\27%M>:WJ>C^%GO+K2K_ %C5;K3]-DU&XF-I:WB68CEL<32L?'SOC'@_./#;
M->#*W$&&P^8X+B]9[DZR?A+%Y;D&*P=2G5PN%RW+Z,8TL1@\-@(UE6S#'9M"
MOF&(4*]2C_:6(J4V_HN&?#KQ"X>\:,A\1Z'"F,Q63YGX>RX5XBEQ#Q_@,YXK
MP.8TJ]''8W.<WQ,GB,'F6,S6>'>'RK*^'ZF$RK"NIAJ6(62X.E54?SS\2A;;
M_@L3I;0HB&7XF^'2^U>&:Y^$<4<SD=WD5CN;U (Q@5_0[7Y5ZA_P3(NK_P")
M;_&J3]J#XF?\+=/B"#Q/'XV?PIX+,L6KVMO%:6DR:7#:V^GB"WM(8K%+%46Q
M-@BVAMO++;OT0\!^&?'GAWP:=#\:?$E_B'XK5M1,7C:Y\(Z+X9DV7&[^S4G\
M/:'*NES-IF5#R(\#7X7]\(V9FKYWQ5SSAGB/!\"SR+B"AF%?AOA'*>%<PP]3
M+<YP-:IB<')2J8_#3QF$]A5P"]Z/OUJ6,246L+)2M#[#P)X8XTX.S+Q2AQ1P
MEBLIPW&GB#G_ !WE&+HYSPWF>&HX+,8<E'*L;3R['+%4,VDU&;]EAJ^7-RFI
M8Z$H7J_B+_P4E(/[<_[-X!!*Z5\,,@$$C=\6=3*Y Y&0IQG&>V<''[R^(R5\
M/:ZRG!71M4(. <$6,Y!P00<'L01ZBOS9^)?_  3DUOXQ^/-'^*/Q'_:<\:ZO
MX^T"VT>VT?6M*^'_ ('T"UTM- U*?5](^P:59H]M&+/4[F>]4W+W<LLTC">6
M2/;&OV9K_P //BYJ7PO\/^"])^.USH_C:R6WM_$WQ0G^'/A;5M0\46:VU[;W
MD?\ PBTLUMH&BW5Z\]K*UW9I+]G-F1%#_I,C+?&N<<,YQP]X49+EW$F"K8CA
M/*\3DV=5JN79]A\+1GB<SGFBQM"=3+I5<5@H1BL-+V6'6,=:I3E'"NBYU*<^
M&W#W&O#O%WCQQ+G'!F8X;!\?9Y@>(^&\-0SCA;%X[$4L'D='(GEN*I4<WC0P
M.9U)R>-A[?%RRZ.&I582QZQ*ITJWXJ?\$;#GXR_&+_LF.CG_ ,NT5]5?\%BP
MW_"B?ADP#;1\7;0,P!V@MX0\5;03T!8!L ]0#CH:Z3X*_P#!-_Q=^SMXGN?%
MWPB_:AU[0]5U.T@TK7(=5^%GA;7-.UK1HKZ*_;3[NVN]8!A)EC<PWEK)#=6[
MRLT<F"4/M_[5W['6K_M6WFAV&O?&WQ!X0^'^@26VI6G@/1?"'A^]@D\210W]
MI/XAN->O)X]2GN7L+][.UM)%>RL8S</%$\MR[I]OG?''!6-\=LC\0L/Q)AY<
M.X:G@:V*F\KSZ.-P\\JRC&9?+#2P;R]2J5<;5QT)X.=&K/#JG1KO%U,-)4H5
MOR_AGPP\2LM^BQQ/X18S@S%4^,,95S3#8&G'/>%9Y9BJ>?<19=F\<9',8YM*
M%'#Y;A\MJ0S&EB*%/%NMB,-' 4L;"5:>'H?L'R:##^PA\*YO%2Z<WAB#P;XS
MG\1+K$$-SI1T.'Q1XKEU4ZG;W$<L$]@+%)S=Q31R126XD5T920?F;P'^V+\5
M_P!K/XG77P2_9'TOPO\ !;X;>&=*DU'5?B?XAT*UUCQ!8>$K>]BTV"[\+>!U
M-KX?TJYU2:XBAT;2[U-1DA0/>WTFG+!);5]G_ G]E>X^#GPS\0?!C6_BOXD^
M)OPLU?P[JWAK3?"NO:!X>T>3P[I_B$ZF/$$-AK6C0QZI<P:FFJW(%M?3SI8R
M,TEFT08H/ECX6_\ !,/5?@IXYO/%OPL_:F^(G@JVO;6XT:X@TKPAX6GUNZ\-
M7$\4_P#8U[JFJ2:AHUU-"\,,L.IR^%S)!=0QWEO;PR[L_.X/-?#2MG'BAF^9
MYOAL3FN8YIC,UX"KYMDN?9APW2JYGB<5BJN+Q^1TH1E6S;!PK+"TX9CA:^!B
MU3J4_KE'VE,^QS+(?&G#</\ @?P_DF08S!9#DV1Y=D7BKA<AXEX5RGC.O0R3
M!8# 4,!E/$U>I*GAL@S"IA98^M4R?&X7-*D'4HU7EV(]E6/A'5/!O_"O_P#@
MJA\/O"UQXU\2_$*[L?B+\-;C5/%WC2_M=0\1ZKJ^I^#+.]N_[1GM+6QLH1!/
M<1P:=86MI!!I]BMG8VR%84)^J?\ @LA9ZCJ7PZ^!NOZ<YN_#%CXV\5:?J5W:
M2B>RBU;4]#@71FFEA+1[VCTO7+:)BWR3&2'&]SCW;XQ_\$Q_AE\1M6\)>*?!
MWQ!\<_#+QMX>C']M>-+68>)_$?C/4EO9=27Q9KVJ:A=V.HGQO]OGGF;Q';7D
M9,36]FEBEKI^GQ6WUA:?LR_"9/@'IO[.&K:$_B+X;Z?H,6C-;ZO</+JMS=)<
MR:C+XC;4X?)N+;Q'-K4T^MC4K(V\D&HS/);K'%B*O>S#Q2X3I9[X2<98;,,P
MS;,>#\MI\/Y[E%3)(Y=5EA80S"AC,XH5U4IY;"K7CBZ=?+,MPE**IQBZ6*G@
MY0Y'\IE/@7Q[7X5^D#X<XW*LHR#)_$3.ZO%G"O$%+B6>;T*>-JSRC%9=P]BL
M)*C6SJ=#"3R^MALZSG'8B<JTZBKX&EF,:CJ+QG_@G=\6O#7Q-_9<^'.F:5>V
MQ\0_#?1;/P#XNT9)(Q>:7?Z'&UMIUU-;!O-6RUK28[34K&Z*"&<RW,".T]I<
MK']5>(?B=X \)^+/!?@/Q#XITO2_&/Q#N-1M?!?AR:21]4UZ72;*74-1:UMX
M(I3%;VMK#(\EW=FWM#(!;I,UPZ1-^4 _X)0^*/ ?B^7Q/\ _VH?&'PX67S(X
M7GTBZ_M^TLV?<EA<:YX;U_P]#K-M'UV7VEQJ[ .R,^YV^R_V>/V,O#OP8\5W
MWQ4\:>/?&/QP^-6I:>^DR?$?Q_=2W%QHVDS*!<Z9X8TV:ZO_ .R(;KF.ZN)+
MZ\NY+?-M!+:VLMS;S_"<:9=X8XC,\^XER?C;%9CALWGF.99=PSA\@S+"YSA\
MVS*=;$QPV/S#,(1RG#Y7A,=BJU:O7A+%8^KA8K!X>B\1*.-C^I>&N;^-V$R7
MA;@OB+PSP&48WA^GD^2YOQMBN+,EQW#>,R')J6'P4\;E.493.7$&+SW,,LP.
M&P^&PM6G@,JP^.G+,<9B5A(2RVI^%&K7V@?##_@HQXGO_C3I.EZGX2M_C_XJ
ME\7VOB?38=6T=O#'C.ZU%M*UR^L+^":"\T^PTW7=)UI9);>5([>U,Z*S0J:_
MHS7]G']FW5K2VN8_@?\ !:_L;F**\L[FW^'7@N:WGAN(MT-U;7$&DLDL,T$H
M>*:)V22-PZ,58&OG_P#:Z_8&^'7[4]Y:>+EUF\^'_P 3+"PCTL>+-.L(=4L-
M=TRW,C6FG^*-#EGLAJ/V)I'2PU*UOK+4;2"1[9YKJT6"VA^=/AM_P3C^/_A"
MPC\'WO[:_P 0]#^&P7RKCPK\/8];TB22U8XELM-N=4\17MKH$$L64)L;.:)"
MQQ;$C)^XXGXLX3X_R#A+,Z?B%C> >(N'\BPF19QDT\+Q35PN-A@:>'A#%Y8^
M'<31IU:TO83=!5'2YZ6(6%Q,\//"QJU/S'@C@'C_ ,)N*^/\CK>$F6^*W!O%
MO%68<4\.\1TL?P+0Q^65,UK8JK6R_.UQC@\17HX>'UFFL3*BL1[*O@Y8W!T\
M72QTZ%']2? ?@OX?^ M'N-!^&_AOPOX5T%=4O;BZTGPEI^G:9IJ:RWE0:A+-
M:::D<":A_H\,-YO03AH424 H!7X1_P#!)R6-/VI/CQ"S!9)O!'B%HU) 9A!\
M3-/$N 3DE/-3=@';GYB,C/[?_![X-> /@5X)L_ 7PYTF;2]$@N;G4KN>]O;G
M5-8UO6[\1G4M?U[5+QY+K4]9U)XTDO+N5E5BJ1PQ0P1111_GCXO_ ."9^L:3
M\9]3^,G[.GQ[UGX*:CK6I:KJUSIR>'O[:_LFXUV?[5K=IH]Y!J^FK<:'J-S)
M-/\ V%K%G>V]NQCC2>2**%8/E.!^(^&*67>*W#.<<28S!T^-,JP>&R?B7.\O
MQ^)=;$Y;F"Q49YQ0P%;-\=AZF,A"+BU6QTH+EIU*TJU-J7WWB?P?QOB,W\!N
M->'N#<OS&MX;9_F..XAX+X:S;*L%]7P><Y/++Y4N'L5FN&X?RO%TLNJ5)*49
M8?*HU6IU:.&AAZJ<.>_X+':M:P?!OX4:(UTBWVI?%"2_ALO-C$LUKI?A76X[
MF[\@N)7@M9M0M(GE6-HXYKJ!)&1I8P_UG_P3R_Y,Q^ __8M:M_ZEOB&O%?BM
M_P $W['XK^#M'T[Q-\9?%GB;XFR^*=,U?QA\9?&NFQ>(/$5[X<T_3]5ME\&^
M#M!@O].T#P3X?:\OX+_^S[".6.>[M_M6IOJ4XA:'ZA_9Q_9CT+]FS0D\/^'?
MB)\4O%^F1Z:NG6VC^-?$\>H>&='!OI]1N+CPWX:LK"QT[0I;NZN)GN#;B5I%
MD96<Y)K3B#B#@U^#N2<$Y;Q!6QV=9/Q5FF<U%_8F8X?#X^%=5*#E1JUJD%@\
M/46(]IA)8[VF*K4<+4GB,+@YXC#T:>/"?"7B-'Z17$OB;G/"6'RSAKB'@+(^
M&Z+_ -9LGQ>,RNIA9T\7R8FA0I3>8XJB\+[+,(97[' X?$8ZC3P>.S*EA,9B
MJOXA_L6QN_\ P4UUMEQB+QQ^T?*^64'86\70Y4$@N?,E0;5!;;N?&Q&8?O'^
MTW_R;E\>/^R0?$7_ -1+5J^%_B)_P37UB[^/^I?'GX'_ !VU3X-ZQKFM:CXB
MO8(/#":U>:-K&O12P>))_#]ZNKZ=!]@UM+N^DGTG4[.Y@BDNYXEE>U>.&#Z
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M$\#^&QKVHZ$LXG@L;C4=6N]5T9;^T9I#::W#X=6YM9I))K2&W\^6(]?\5?\
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MS'-XXU3QWU2$Z-&O6QV*H/\ +>%/!+B?*>)^!N(>%.#N+?"OBZAQ1@,5XDK
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MRY(12480BHIN7=AN%).7/B9SQ%1OWJE1:O962O9)+1*[M>^IX[I/@T*1NBP
M><@Y[=3@Y)Z$?Y/IVD^&HXPI$6!QD8./0\< @#WR/4<5W5MHT:8)3G QSQD#
M(R.N#UX&?UK>@L0N. , ')('''KQU'3WSP<5^=XW.ZM>_ONSONW^2>OX'U>"
MR2AATDH*Z[+3[_S,BQTQ80I"CMT')(YXQGDXR.>N>XQ71PP*JC@=MJ\D#(Y/
M/;/4_P!0*FCB"8Q^)(Y'<8Z9Z^F,Y//%3  =._4]R?>OG:M>51MMMWW;>K_K
M^NI]#2H1@EHO*RT^6EP"@?R]/P ' %+116!T&1KV@Z-XHT;4O#WB+3+/6-$U
M>UDLM2TR_A6>UN[:4?-'+&W0@A9(I$*RPRI'-"\<L:.OPE\1O ]_\)I+:SWW
M%[X*NYEMM \07#M+/87$G$.@>(K@C_C[.!'I6JR[8]311;SLNH)^_P#T$K,U
MK1=*\1:5?Z'KEA;:II&J6TMGJ%A=QB6WN;>48>-U."".'CD0K)%(J2Q.DB(Z
M[X:M&C6ISG%SIQDG.">MG92<;Z*:6S>CM9Z.ZYL90GB,-5HTZGLJDX24)ZM*
M=GR\R6KBW92M[R3;CJDG^*7Q#TX7(GU#3U"W.'>ZM4 Q, .98@" )QR6CZ2G
MD8D^_P"1?#GX[^)O@CXM?Q#HL;:OH=^\47C#PA-,8+3Q!8Q':L]O(^8M/\1Z
M?$S'2]3("MS8:@)+.4B+ZA_:!^%FO?!;48YFDN]8^'>KW:VWA[Q-<$S7&CW<
MQ/V?POXHG  6ZQ\FB:S+MBUB-1:W#1ZHF+CXY^#7[-WC7]JGXH:Y;P7&H^'O
MAGH>N3P^,?%BL^V&&.?<?#7AT/FWN]?O8AG[DEIH]M*+^]5Y'M;2\_H_A6AD
M%?(\7CLWQ.$CP]3P;J8O$5TY0=-S]F\*J4)*N\=[7EIX>A2Y<7'%^Q5&S4:Q
M_'_&N.XNPO%&#R?(<'CGQ;+&PCEV'PSC&3FTZD<6ZU6+PRRQ4.>KB\374L"\
M%]86(37-0?[F?#7QCX(^+O@[2O'G@/5H]8\/ZL)$60H8;[3M0MF$6HZ+K-DS
M&2PUG2KC-K?V,IW12!7B>2"2&:3TRVTV.+;A.QYQSP<# YQQUXR>ISGFCX!^
M'7@[X8>$M%\#^!M#MM \-:#:BVL+"T Y8_-<7EY,Y::^U&^E+7%_?W;RW5W<
M.\TTCNV1V:Q!>G'M@'C^6>?0\^V /P#,<7A)XW&++?K:RWZS7^HQQTJ3Q:P?
MM9?5UBG0M2==4N3VGLUR\UMY*;E_5V4X3,(9=E_]L_499O\ 4\-_:CRR%>&7
MRQ_L*?UMX)8EO$1PKK\_L56?/R]%!TU&M!"$ W#.!A1GJ<X_(^O3@XZC%U1@
M<]3U_P ![#H/:@ #)[GJ>Y_SZ=!VI:\J4G)W9[,8J*L@HHHJ2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!" <\=>_?\ .F&-3P<'''09_'L??@9HHHO8F25GZ,A,",#Q
M@!1QU'/S?GQCTY)Q51K>/:3M&""<8Z8., ^G/IUYHHK2,Y*_O/1-[]2'"+>J
M6Z_)O\RNUM$#]T>O08_$'.>@^N.:3[)$,L%&XCDXZYVY!YY!ST/'8BBBMU.6
MNKV,7&-]NMNNV]OO'I:Q*2 .F.P&><]A^&.G3CBK2VR=>,KG'R@=\=<Y[D]:
M**SG.>OO/9?B[%QC&ZT6_P#D6EB520!R.<X]<9 [@?CTX]ZF"@>_IGM]!T'Y
M445BVWN[FT4DM%W%HHHI%!1110 4444 8WB+P]HGBW0]5\->)-,M-9T'6[*;
M3]4TN_B$UK>6DZ[9(I$."".'BEC9)H)5CFADCFC1US/ _@;PI\-_#&E>#?!6
MBVF@>'-%@\BPT^T#L%W,9)KBXN)GDN;V]NIF>>\OKN::[N[AWGN)I)'9B45L
ML1B%0>$5>LL+*K'$2PRJU%AY8B$'2C7E14_9.M&E*5.-5P<U"3BI),YWA,*\
M5''/#8=XV&'EA88QT:3Q4<+.K&M/#1Q#I^VC0G6A"K*BJJIRJ1C-P<DF=911
M16)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
